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A B S T R A C T
Background
Osteoporosis is a bone mineralisation disorder occurring in about one third of adults with cystic fibrosis. Bisphosphonates can increase
bone mineral density and decrease the risk of new fractures in post-menopausal women and people receiving long-term oral corticos-
teroids.
Objectives
To assess the effects of bisphosphonates on the frequency of fractures, bone mineral density, quality of life, adverse events, trial
withdrawals, and survival in people with cystic fibrosis.
Search methods
We searched the Cystic Fibrosis and Genetic Disorders Group Trials Register of references (identified from electronic database searches
and handsearches of journals and abstract books) on 13 January 2014.
Additional searches of PubMed were performed on 13 January 2014.
Selection criteria
Randomised controlled trials of at least six months duration studying bisphosphonates in people with cystic fibrosis.
Data collection and analysis
Two authors independently selected trials and extracted data. Trial investigators were contacted to obtain missing data.
Main results
Nine trials were identified and seven (with a total of 237 adult participants) were included.
Data were combined (when available) from six included studies in participants without a lung transplant. Data showed that there was
no significant reduction in fractures between treatment and control groups at 12 months, odds ratio 0.72 (95% confidence interval
0.13 to 3.80). No fractures were reported in studies with follow-up at 24 months. However, in patients taking bisphosphonates after six
months the percentage change in bone mineral density increased at the lumbar spine, mean difference 4.61 (95% confidence interval
3.90 to 5.32) and at the hip or femur, mean difference 3.35 (95% confidence interval 1.63 to 5.07); but did not significantly change at
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the distal forearm, mean difference -0.49 (95% confidence interval -2.42 to 1.45). In patients taking bisphosphonates, at 12 months
the percentage change in bone mineral density increased at the lumbar spine, mean difference 6.10 (95% confidence interval 5.10
to 7.10) and at the hip or femur, mean difference 4.35 (95% confidence interval 2.99 to 5.70). At 24 months, in patients treated
with bisphosphonates the percentage change in bone mineral density also increased at the lumbar spine, mean difference 5.49 (95%
confidence interval 4.38 to 6.60) and at the hip or femur, mean difference 6.05 (95% confidence interval 3.74 to 8.36). There was
clinical heterogeneity between studies and not all studies reported all outcomes. Bone pain was the most common adverse event with
intravenous agents. Flu-like symptoms were also increased in those taking bisphosphonates.
In participants with a lung transplant (one study), intravenous pamidronate did not change the number of new fractures. At axial sites,
bone mineral density increased with treatment compared to controls: percentage change in bone mineral density at lumbar spine, mean
difference 6.20 (95% confidence interval 4.28 to 8.12); and femur mean difference 7.90 (95% confidence interval 5.78 to 10.02).
Authors’ conclusions
Oral and intravenous bisphosphonates increase bone mineral density in people with cystic fibrosis. Severe bone pain and flu-like
symptoms may occur with intravenous agents. Additional trials are needed to determine if bone pain is more common or severe (or
both) with the more potent zoledronate and if corticosteroids ameliorate or prevent these adverse events. Additional trials are also
required to further assess gastrointestinal adverse effects associated with oral bisphosphonates. Trials in larger populations are needed
to determine effects on fracture rate and survival.
P L A I N L A N G U A G E S U M M A R Y
Bisphosphonates for osteoporosis in people with cystic fibrosis
Cystic fibrosis is a serious genetic disorder that affects many organs (e.g. lung and pancreas). It commonly leads to reduced bone mineral
density, known as osteoporosis, which increases the likelihood of fractures. The short-term and long-term effects of fractures (e.g. rib
and vertebral) may make lung disease worse. Bisphosphonates are drugs that increase bone mineral density by slowing down bone
resorption. They are used to treat osteoporosis caused by menopause or the use of corticosteroid drugs.
The evidence available was limited to six trials with participants who had not undergone lung transplants (total of 203 adults) and
one trial with 34 adults who had undergone lung transplantation. Bisphosphonates consistently increased bone mineral density at
the lumbar spine and hip regions. The rates of fractures (vertebral and non-vertebral) or deaths were not reduced by bisphosphonate
therapy. However, this may be related to the small numbers of participants involved and the short duration of the trials. Severe bone
pain and flu-like symptoms were commonly linked to intravenous bisphosphonates, especially in people not using corticosteroids.
More research is needed to assess the effect of pre-treatment with corticosteroids. Additional trials are needed to determine if bone pain
is more common or severe (or both) with the stronger drug zoledronate and if corticosteroids lessen or prevent these adverse events.
Additional trials are also required to further assess gastrointestinal adverse effects associated with oral bisphosphonates. Trials in larger
populations are needed to determine effects on fracture rate and survival.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the most common serious autosomal reces-
sive genetic disorder in the Caucasian population. It is caused by
mutations in the cystic fibrosis transmembrane regulator (CFTR)
gene (Riordan 1989). This genetic disorder occurs in approxi-
mately one in 3500 live births in the United States of Amer-
ica; the incidence varies between racial and ethnic groups, being
more common in Caucasians (Cystic Fibrosis Foundation Patient
Registry 2013). One in 25 individuals carry the defective gene
(Yankaskas 1999). The major components of CF are lung disease
and pancreatic insufficiency. In the past, only one third of indi-
viduals with CF lived to the age of 18 years (Yankaskas 1999).
However, recent advances in medical science and technology have
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increased the life expectancy of people with CF into the fourth and
fifth decades of life (Cystic Fibrosis Foundation Patient Registry
2013). In the United States of America, the predicted median sur-
vival in 1992, 2002 and 2012 was 29.4 years, 31.3 years and 41.1
years respectively. Hence, as survival improves, long-term sequelae
of the disease (Quon 2012), such as osteoporosis (Paccou 2013;
Stalvey 2013a), diabetes mellitus (Kelly 2013) and liver disease
(Rowland 2011) are of increasing significance.
Osteoporosis is a disorder of bone mineralisation that decreases
bone mineral density (BMD) and makes bones brittle and more
susceptible to fracture. Osteopenia refers to a milder degree of
bone demineralisation. Bone density is currently measured using
dual-energy X-ray absorptiometry (DXA), which measures abso-
lute bone density in grams per centimetre squared (gm/cm2) and
can be compared to a population mean. It is usual to express BMD
as standard deviations from the population mean, either as a Z-
score (compared to age- and sex-matched data) or a T-score (com-
pared to the healthy young adult mean for the participant’s sex).
The World Health Organization (WHO) classifies osteopenia as
a T-score of between -1 and -2.5, and osteoporosis as a T-score of
-2.5 or less (Kanis 1994). The International Society for Clinical
Densitometry has recommendations with regard to BMD report-
ing (ISCD Official Positions 2013). However, BMD is only one
of the factors that determine the risk of fracture. It is osteoporotic
fractures which account for the morbidity and mortality associ-
ated with osteoporosis (Cummings 1995).
Decreased BMD has been observed in children with CF (Bianchi
2006; Sermet-Gaudelus 2007), adolescents with CF (Bianchi
2006; Buntain 2004; Caldeira 2008) and adults with CF (Bianchi
2006; Buntain 2004). A longitudinal study of 151 adults with
CF aged 15 to 52 years showed that 34% of participants had a
DXA Z-score of ≤ -2 (Haworth 2001). A recent systematic liter-
ature review with meta-analysis reported the pooled prevalence of
osteoporosis (total of 888 patients) and osteopenia (total of 697
patients) in adults with CF was 23.5% (95% confidence inter-
val (CI) 16.6 to 31.0) and 38% (95% CI 28.2 to 48.3) respec-
tively (Paccou 2010). Other studies have not detected differences
in BMD between children with CF and those without (Buntain
2004), but inadequate bone mass accrual during childhood and
adolescence has been reported (Buntain 2006). Definitions of os-
teoporosis and osteopenia may vary between studies.
The etiology of CF-related bone disease is thought to be multifac-
torial. An imbalance of increased bone resorption and decreased
bone formation has been observed (Boyle 2006; Gore 2010), even
in young prepubertal patients (Ambroszkiewicz 2013). Proposed
contributing factors to bone disease include malnutrition and
exocrine pancreatic insufficiency; vitamin D, vitamin K or cal-
cium deficiency; poor nutrition and growth resulting in low body
weight; systemic inflammatory cytokines; use of exogenous gluco-
corticoids; sex hormone insufficiency, diabetes mellitus, physical
inactivity resulting in decreased weight bearing activity and organ
transplantation with associated immunosuppressive therapy (Aris
2005; Boyle 2006; Gore 2010; Hall 2010; Haworth 2010b; Javier
2011; Paccou 2013). Abnormalities of calcium metabolism inde-
pendent of vitamin D status have been reported (Greer 2003).
Many of these factors are inter-related (e.g. pancreatic exocrine
insufficiency contributing to malabsorption of vitamin D, exac-
erbated by decreased sun exposure if indoors due to poor health).
Furthermore, BMDhas beenpositively associatedwith pulmonary
function, physical function, nutritional status and negatively as-
sociated with chronological age and recurrent pulmonary exacer-
bations (Alicandro 2013; Donadio 2013; Legroux-Gerot 2012).
Mutation of the CFTR gene itself may have a direct role in the
pathogenesis of CF-related bone disease (Dif 2004; Le Henaff
2012; Paccou 2013). Studies have indicated that the loss of CFTR
activity in osteoblasts decreases the secretion of osteoprotegerin
(OPG) resulting in accentuated inflammation-driven bone resorp-
tion (Le Heron 2010; Stalvey 2013).The glycoprotein OPG acts
a decoy receptor for receptor activator of nuclear factor κB ligand
(RANKL), blocking the interaction of RANKL with the receptor
RANK.TheRANKL/RANK interaction stimulates the formation
and activation of osteoclasts, hence OPG exerts an anti-resorptive
effect (Weitzmann 2013). A recent study identified that the risk
of osteoporosis was related to gene polymorphisms of the gene en-
coding the inflammatory cytokine, tumour necrosis factor-alpha
(Shmarina 2013).
The clinical consequences of CF-related bone disease include low
bone density with potential fractures, including rib and vertebral
fractures, which may be precipitated by coughing. In the system-
atic review by Paccou, the pooled prevalences of radiological ver-
tebral fractures (total of 683 patients) and non-vertebral fractures
(total of 553 patients) in young adults with CFwere 14% (95%CI
7.8 to 21.7) and 19.7% (95% CI 6.0 to 38.8) respectively (Paccou
2010). A study in post-lung transplant participants with CF found
an approximate two-fold increase in the risk of non-vertebral frac-
tures for women aged 16 to 34 years (P = 0.015) and men aged 25
to 45 years (P = 0.04) compared with the general population (Aris
1998). Vertebral compression and rib fractures were 100-fold and
10-fold more common respectively than predicted (P < 0.001). In-
cident new vertebral fractures are commonly defined as a 15% or
greater reduction in anterior, posterior, or middle vertebral height.
Acutely, vertebral and rib fractures may result in pain and debil-
itation, resulting in diminished lung function, ineffective cough
and airway clearance, limitations in respiratory physiotherapy, in
addition to reduced physical activity. Chronic consequences may
include kyphosis and chest wall deformities which may worsen
lung function. Hence a vicious cycle of further impairment in lung
function and deterioration in bone health may result (Aris 2005;
Boyle 2006; Hayes 2011). Established bone disease may exclude
the patient from lung transplantation, as the high-dose corticos-
teroids and other immunosuppression required post-transplanta-
tion can be expected to worsen bone disease further (Aris 1996).
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Description of the intervention
Bisphosphonates are a class of drugs that inhibit bone resorption
(Giger 2013; Russell 2007). Considerations in using bisphospho-
nate therapy include different formulations (oral, intravenous),
dosage, frequency of administration, intermittent versus continu-
ous dosing and duration of therapy (Russell 2006).
Potential side-effects include an acute-phase response leading to
fever and ’flu’-like symptoms (myalgia, malaise). This has been
most commonly observed after the first exposure to nitrogen-con-
taining bisphosphonates administered intravenously, and associ-
ated with an increase in inflammatory cytokines (Sauty 1996).
Osteonecrosis of the jaw has been associated with high-dose in-
travenous bisphosphonate therapy in patients with malignancy
(Pendrys 2008). Prolonged bisphosphonate use (exceeding five
years) has been associated with atypical femoral fractures, a rare
subset of subtrochanteric and femoral shaft fractures (Saleh 2013).
Upper gastrointestinal side-effects (e.g. oesophagitis) have been
associated with oral agents (Cryer 2002).
How the intervention might work
Bisphosphonates are selectively taken up by bone and exert in-
hibitory effects on osteoclasts, cells that act to dissolve and resorb
bone (Russell 2007). Individual drugs within this class have dif-
ferent mineral binding affinities and molecular modes of action
(e.g. nitrogen-containing pamidronate, alendronate, risedronate,
ibandronate and zoledronate are more potent than the non-nitro-
gen containing etidronate and clodronate) (Russell 2006).
Bisphosphonates have proven effective treatments for disorders of
excessive bone resorption (Giger 2013). These disorders include
Paget’s disease of bone, myeloma, bone metastases (Russell 2006);
postmenopausal osteoporosis (Black 1996); other forms of osteo-
porosis (e.g. associated with glucocorticoid administration (Saag
1998)); and children with the ’brittle bone’ disorder, osteogenesis
imperfecta (Glorieux 1998; Phillipi 2008). Positive outcomes have
included increased bone mass, BMD and a reduction in fracture
frequency.
Bone resorption has been observed to increase during CF pul-
monary exacerbations due to the stimulatory effect of pro-in-
flammatory cytokines on osteoclast activity (Shead 2010). Loss
of the CFTR in osteoblasts may exacerbate the effect of inflam-
mation to stimulate osteoclastogenesis (Le Heron 2010; Stalvey
2013;Weitzmann 2013). Since bisphosphonates inhibit osteoclas-
tic bone resorption, these agents may minimise bone loss in this
context.
A two-year study of intermittent cyclical etidronate in 423 post-
menopausal women demonstrated a significant increase in BMD
at the spine and a decrease in new fractures (Watts 1990). In a
study of 2027 women with at least one existing vertebral fracture,
alendronate was shown to increase BMD at the spine and hip and
to decrease fractures at the hip, wrist and spine after three years
of treatment (Black 1996). Pamidronate in combination with cal-
cium was studied over an 18-month period in an initial cohort
of 35 postmenopausal women (mean age 64.5 years) with at least
one atraumatic vertebral fracture due to osteoporosis. After one
year, BMD increased in the lumbar spine (P < 0.001), although
there were no changes in the femoral neck (Fromm 1991). Oral
risedronate has been observed to secondarily prevent vertebral and
non-vertebral fractures in postmenopausal women (Wells 2008).
A study of 477 participants with glucocorticoid-induced osteo-
porosis found alendronate to be highly effective in increasing
BMD at the spine and femoral neck, with a significant reduction
in the number of incident fractures (Saag 1998). Another one-
year study compared two regimens of intravenous pamidronate (a
single infusion or once every three months) for the primary pre-
vention of glucocorticoid-induced osteoporosis. The study popu-
lation consisted of 32 participants who required long-term gluco-
corticoid therapy with at least 10 mg of prednisone daily. A highly
significant difference was observed between both pamidronate reg-
imens and the control group at the lumbar spine (P < 0.001)
and femoral neck (P < 0.01). Both pamidronate regimens effec-
tively achieved primary prevention of glucocorticoid-induced os-
teoporosis (Boutsen 2001). This evidence is particularly promis-
ing since corticosteroid use is associated with osteoporosis among
people with CF.
A three-year randomized double-blind trial of 300 mg oral
pamidronate daily compared with placebo was conducted in 105
participantswith rheumatoid arthritis (Eggelmeijer 1996). Inflam-
mation, decreasedmobility and glucocorticoid usemay contribute
to the risk of osteoporosis in individuals with rheumatological
conditions. After three years, lumbar spine and forearm BMD had
increased significantly in the pamidronate-treated group, while
there were non-significant changes in the placebo-treated group.
Changes were significantly different between the treatment and
placebo groups (Eggelmeijer 1996).
Why it is important to do this review
This is an update of a previous Cochrane review (Brenckmann
2001; Conwell 2009; Conwell 2012).
A multi-faceted approach to the prevention and treatment of low
BMD has been recommended including optimising vitamin, cal-
cium and nutritional status, encouraging weight-bearing exercise,
endocrinological assessment and management of delayed puberty
or hypogonadism, aggressive treatment of pulmonary infections,
minimizing exposure to corticosteroids and treatment of CF-re-
lated diabetes (Aris 2005). A consensus statement addressing the
issue of bone health and disease in CF recommends consideration
of oral or intravenous bisphosphonates in individuals with DXA
T- or Z-scores ≤ 2.0, awaiting transplant or BMD loss more than
3% to 5% per year (Aris 2005). A caution is placed on the use
of intravenous bisphosphonates due to the association with severe
bone pain in this population group.
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The UK Cystic Fibrosis Trust Bone Mineralisation Working
Group outlined specific recommendations for consideration of
bisphosphonate treatment in adults and children, justifying the
importance of the previous Cochrane reviews of the available ev-
idence assessing bisphosphonates for osteoporosis in people with
CF (Cystic Fibrosis Trust Report 2007).
The more recent European Cystic Fibrosis Bone Mineralisa-
tion guidelines outline detailed recommended assessment, preven-
tion and treatment strategies (Sermet-Gaudelus 2011). Specifi-
cally, these guidelines recommend consideration of bisphospho-
nate treatment in adults who:
1. are taking continuous systemic oral glucocorticoids for at
least three months with a BMD Z/T-score of -1.5 or less;
2. sustain a low trauma fracture while taking systemic
glucocorticoids;
3. have had a low trauma fracture or in whom the lumbar
spine or total hip or femoral neck Z/T-score is -2 or less (or
both) and there is evidence of significant bone loss (more than
4% per year) on serial DXA measurements despite optimisation
of clinical care;
4. are awaiting or have undergone solid organ transplantation
and have a BMD Z/T-score of -1.5 or less;
5. are starting a prolonged course of oral glucocorticoids
(longer than three months) and have a BMT Z/T-score of -1.5
or less (Sermet-Gaudelus 2011).
These 2011 guidelines also recommend the consideration of bis-
phosphonate treatment in children after failure of optimal conser-
vative treatment who:
1. are taking continuous systemic glucocorticoids for at least
three months and have a history of low trauma fracture or BMD
Z-score of -2 or less (or both);
2. have a BMD Z-score of -2 or less in the total body or
lumbar spine and a history of low-trauma extremity fractures or
vertebral compression fractures;
3. are awaiting or have undergone solid organ transplantation
and have a BMD Z-score of -2 or less;
4. are prescribed continuous systemic glucocorticoids and
have a BMD Z-score of -2 or less (Sermet-Gaudelus 2011).
In transplant recipients, the recommendations are that:
1. low BMD and a history of low trauma fractures are not an
absolute contraindication for lung transplant listing in people
with CF;
2. bone loss after solid organ transplantation can be lessened
by the prescription of bisphosphonates in people with CF
(Sermet-Gaudelus 2011).
Hence, a review of the available evidence assessing bisphospho-
nates for osteoporosis in people with CF is important.
O B J E C T I V E S
To determine whether bisphosphonates cause the following
changes in people with CF:
1. decrease fractures (vertebral and non-vertebral);
2. improve BMD measured using DXA or, if available, using
other methods of bone density measurement such as single
energy X-ray absorptiometry (SXA) and quantitative
tomography (QCT);
3. increase quality of life;
4. increase adverse events, including bone pain and
gastrointestinal adverse events;
5. change the number of withdrawals due to all causes and due
to adverse events;
6. increase survival.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials. Published papers and abstracts were
included. Trials published in all languages were considered for
inclusion.
Types of participants
People of all ages and of both sexes with CF diagnosed clinically
or by sweat and genetic testing, including all degrees of disease
severity and bone density.
Types of interventions
All trials examining bisphosphonates compared to controls (other
bisphosphonates, placebo or usual treatment) for treating or pre-
venting osteoporosis in people with CF were considered for inclu-
sion. All doses and routes of administration were considered. Tri-
als of a minimum duration of six months were included to allow
time to observe an effect of treatment.
Types of outcome measures
Primary outcomes
1. Fractures (number of participants with any fracture and
number of fractures at all sites, spine, hip, wrist)
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Secondary outcomes
1. Bone density as measured by dual-energy X-ray
absorptiometry (DXA), reported as per cent change from
baseline. Data reported using other methods of bone density
measurement such as single energy X-ray absorptiometry (SXA)
and quantitative tomography (QCT) would be used if available
but analysed separately:
i) lumbar spine
ii) hip or femur
iii) radius
iv) total body
2. Quality of life (QoL) (CF-related, osteoporosis-related or
general QoL measures)
3. Adverse events such as bone pain, hypocalcaemia and
gastrointestinal adverse events (number of participants, number
of adverse events)
4. Withdrawals
i) withdrawals due to adverse events
ii) total withdrawals
5. Survival
Search methods for identification of studies
Electronic searches
Relevant trials were identified from the Group’s Cystic Fibrosis
Trials Register using the terms: CF-related bone disease AND bis-
phosphonates.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (updated each new issue), quarterly searches of
MEDLINE, a search of Embase to 1995 and the prospective hand-
searching of two journals - Pediatric Pulmonology and the Journal
of Cystic Fibrosis. Unpublished work is identified by searching the
abstract books of three major cystic fibrosis conferences: the Inter-
national Cystic Fibrosis Conference; the European Cystic Fibrosis
Conference and the North American Cystic Fibrosis Conference.
For full details of all searching activities for the register, please see
the relevant sections of the Cystic Fibrosis and Genetic Disorders
Group Module.
Date of the most recent search of the Group’s Cystic Fibrosis Trials
Register: 13 January 2014.
Additionally LC performed personal searches of PubMed on 14
January 2014 (all years up to 14 January 2014) (Appendix 1;
Appendix 2).
Searching other resources
For the original review, abstracts from major osteoporosis confer-
ences (The American Society for Bone and Mineral Research and
The Institute of Biomedical Science (ASBMR-IBM) 2nd Joint
Meeting 1998; ASBMR21st AnnualMeeting 1999)were searched
and also the reference lists from the retrieved articles.
In an earlier update, the reference lists for the retrieved articles
were also searched and from that, a further paper was identified
(Conway 2004).
Data collection and analysis
Selection of studies
In the original review, two authors (CB, AP) independently re-
viewed the trials in order to assess which trials should be included.
For the updated reviews from 2009, two authors (LC, AC) inde-
pendently reviewed the trials included in the original review in
addition to trials identified by the updated searches. If there was
disagreement about whether a trial should be included, the au-
thors planned to ask an independent author from a third centre
to review the paper(s) in question. The authors documented the
reasons for excluding any trial.
Data extraction and management
In the original review, each author independently extracted data for
the outcome measures listed below. The review authors contacted
the first authors of the included trials to verify their data and obtain
unpublished data where necessary. The authors used theCochrane
Review Manager software (Version 4.1) to compile and analyse
the data (Review Manager 2003). The authors compared their
data and resolved differences by referring to the original article;
they planned to resolve any remaining differences with a third
individual.
From 2009 onwards, the authors (LC, AC) reviewed trials that sat-
isfied the inclusion criteria and recorded the following information
when available: study setting; year of study; source of funding; par-
ticipant recruitment details (including number of eligible partici-
pants); inclusion and exclusion criteria; randomisation and alloca-
tion concealment method; numbers of participants randomised;
blinding (masking) of participants, care providers and outcome
assessors; dose and type of intervention; duration of therapy; co-
interventions; numbers of participants not followed up; reasons
for withdrawals from study protocol (clinical, side-effects, refusal
and other); side-effects of therapy; and whether intention-to-treat
analyses were possible. The review authors requested further infor-
mation from the two authors but no response was received. Data
were reported at time-points 6 months, 12 months and annually
thereafter which are appropriate time-points to assess treatment
effects on fracture frequency and duration. For per cent change
in BMD, the review authors combined and reported data for the
end of study as it is unknown what length of study is needed for
effect of treatment to be evident. The review authors used the
Cochrane Review Manager software (Version 5.1) to compile and
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analyse the data (Review Manager 2011). Similarly, the authors
compared their data and resolved differences by referring to the
original article.
The review authors conducted separate analyses for participants
who had received a lung transplant and for those who had not.
At this stage, the number of people with CF who have received
other organ transplants is small. Therefore, the authors included
individuals with other organ transplants in the analysis of partici-
pants with a lung transplant, since they share a common risk factor
for osteoporosis, that is the long-term use of immunosuppressive
agents which lower BMD.
Assessment of risk of bias in included studies
The two authorswhoperformed the original review independently
assessed the quality of the trials using the system as described by
Jadad (Jadad 1996). If there was disagreement about whether a trial
should be included, or about the quality score it should receive,
the authors asked an independent author from a third centre to
review the paper(s) in question.
In this reviewupdate, the authors (LC, AB) independently assessed
the risk of bias in the trials using the criteria described in the
Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011):
1. randomisation process i.e. the generation of allocation
sequence;
2. allocation process i.e. quality of allocation blinding;
3. degree of blinding (of clinician or person delivering
treatment, of participant or of outcome assessor);
4. is attrition bias present i.e. use of intention-to-treat analysis?
5. is selective reporting present?
For each of the criteria, the authors gave a judgement of a high, low
or unclear risk of bias based on guidance fromThe Cochrane Col-
laboration (Higgins 2011) and gave the reasons for these judge-
ments in the risk of bias tables (Characteristics of included studies).
Measures of treatment effect
For the dichotomous outcome variables (adverse events, fractures,
survival) of each individual study, the authors calculated the odds
ratio (OR) using a modified intention-to-treat analysis (where in-
complete data assumes failure of treatment). They also calculated
the summary ORs and 95% confidence intervals (CIs) using the
Cochrane Collaboration’s statistical package, RevMan 5 (Review
Manager 2011). They planned to calculate the numbers needed
to treat (NNT) from the pooled OR and its 95% CIs applied to
a specified baseline risk, which is the sum of all the events in the
control groups (in all trials) divided by the total participant num-
bers in control groups in all trials using an online calculator (Cates
2003).
For continuous outcomes (changes in BMD and laboratory val-
ues), the authors recorded the mean relative change from baseline
for each group or mean post-treatment or post-intervention values
and standard deviation (SD). They planned to calculate the SDs if
standard errors were reported. They would then calculate a pooled
estimate of treatment effect by the mean difference (MD) and
95% CIs, again using the statistical package from The Cochrane
Collaboration (Review Manager 2011).
Unit of analysis issues
There were no cross-over studies, but if there had been, the authors
planned only to use data from the first arm of the study for any
analysis due to the potential for a carry-over effect. They would
have analysed count data of rare events as rates (number of counts
to the amount of time during which they could have happened).
They planned to use the summary statistic rate ratio in meta-anal-
ysis. For rate ratios of common events, whereby one participant
may have more than one event, they planned to use the generic
inverse variance (GIV) method of analysis.
Dealing with missing data
The review authors contacted primary authors of studies to obtain
missing data or clarify data.
Assessment of heterogeneity
The authors planned to describe any heterogeneity between the
study results and test it to see if it reached statistical significance
using the I2 statistic (Higgins 2003). This measure describes the
percentage of total variation across studies that are due to hetero-
geneity rather than by chance (Higgins 2003).
The values of I2 lie between 0% and 100%, and a simplified
categorization of heterogeneity that the authors planned to use
is of low (I2 value of 0% to 40%), moderate (I2 value 30% to
60%), substantial (I2 value 50% to 90%) and considerable (75%
to 100%) (Higgins 2011). The P value from the chi-squared test
also indicates the strength of evidence for heterogeneity, considered
to be statistically significant when the P value was less than 0.10
(Higgins 2011).
Assessment of reporting biases
In order to identify selective reporting, the review authors com-
pared outcome measures reported within the published papers to
the measures described in the methodology sections or with the
study protocols if they were available.
Data synthesis
The authors included the results from studies that met the in-
clusion criteria and reported any of the outcomes of interest in
the subsequent meta-analyses using a fixed-effect model. They
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would have included the 95% CI, estimated using a random-ef-
fects model, if there was at least moderate heterogeneity (I2 over
30%).
If studies reported outcomes using different measurement scales,
the authors planned to estimate the standardised mean difference.
Subgroup analysis and investigation of heterogeneity
The authors planned to analyse the trials in the subgroups of chil-
dren (aged 18 years or less) and adults (over 18 years). There were
no trials fulfilling the definition of the former subgroup, but the
authors will carry out this planned subgroup analysis if they are
able to include a sufficient number of relevant trials (at least 10)
in a future update of this review.
Sensitivity analysis
The authors had also planned to conduct sensitivity analyses to
assess the impact of the potentially important factors on the overall
outcomes:
1. differences in the medications used in the intervention and
comparison groups;
2. analysis using random effects model;
3. analysis by “treatment received”; and
4. analysis by “intention-to-treat”.
R E S U L T S
Description of studies
Results of the search
In the original review (Brenckmann 2001), two studies were iden-
tified. With the present update, a total of nine clinical trials were
identified that were all published in English (Aris 2000; Aris
2004; Boyle 2005; Chapman 2009; Conway 2004; Hardin 2005;
Haworth 2001; Haworth 2011; Papaioannou 2008). Seven tri-
als were identified from the search of the Group’s Cystic Fibro-
sis Trials Register (Aris 2000; Aris 2004; Boyle 2005; Chapman
2009; Hardin 2005; Haworth 2001; Haworth 2011). Additional
PubMed searches as detailed in the appendices (Appendix 1;
Appendix 2) identified one further trial (Papaioannou 2008) and
the full paper to the previously identified abstracts to the later Ha-
worth trial. Searching the reference lists for the retrieved articles
identified a further trial (Conway 2004).
Seven clinical trials were included and two were excluded (see
below).
Included studies
Seven clinical trials met the inclusion criteria for this review (Aris
2000; Aris 2004; Boyle 2005; Chapman 2009; Haworth 2001;
Haworth 2011; Papaioannou 2008). One trial was published only
as an abstract (Boyle 2005). We contacted the lead investigator
for details of the full publication, without receiving a reply. Four
trials were published both as abstracts and full review papers (Aris
2000; Aris 2004; Haworth 2001; Haworth 2011). Two trials were
published as full review papers (Chapman 2009; Papaioannou
2008).
All the trials had similar designs, duration of planned interven-
tion (12 to 24 months) and outcome measures. None of the trials
reported sample size or power calculations. None of the studies
included children (aged 18 years or less). In the Boyle trial, en-
rolment was ceased after five participants were randomised and
follow-up duration was decreased from 12 months to 6 months
due to adverse events (i.e. musculoskeletal pain) (Boyle 2005).
The follow-up duration of another trial was also shortened from
12 months to 6 months due to adverse events (i.e. bone pain)
(Haworth 2001).
One trial assessed 24 months of intravenous pamidronate in 34
post-transplant adults with CF (Aris 2000). The participants in
the other six trials were non-transplanted adults with CF.
Other factors thatwill contribute to the heterogeneity in the results
of the review include differences in trial populations and concomi-
tant general health, activity levels and medications (prednisone,
cyclosporin A, azathioprine in the transplant group).
All participants in six of the trials received supplemental calcium
and vitamin D (Aris 2000; Aris 2004; Boyle 2005; Chapman
2009; Haworth 2011; Papaioannou 2008). In the study by Ha-
worth and colleagues, participants with pancreatic insufficiency
were prescribed long-term oral vitamin D supplements (all par-
ticipants except one participant in the control group) (Haworth
2001). Oral prednisolone was administered to all participants of
one study for three days starting on the morning of the first infu-
sion (Chapman 2009). This was repeated with subsequent infu-
sions if a reaction to the first infusion was thought likely.
The types of bisphosphonate assessed in the trials included intra-
venous pamidronate in two trials, 31 participants in the earlier
Haworth trial and 34 participants in the earlier Aris trial (Aris
2000; Haworth 2001); oral alendronate in two trials, 53 partici-
pants in the later Aris trial and 56 participants in the Papaioannou
trial (Aris 2004; Papaioannou 2008); oral risedronate (36 partici-
pants) (Haworth 2011); intravenous zoledronate (22 participants)
(Chapman 2009) and intravenous zoledronate (40 participants
planned) (Boyle 2005).
Funding for one trial was provided by grants from the CF Foun-
dation and the Verne S. Caviness General Center for Clinical Re-
search (Aris 2000). Another trial was funded by the U.S. Food and
Drug administration, Merck and Co, Inc., the Clinical Nutrition
Research Unit, the Verne S. Caviness General Center for Clini-
cal Research at University of North Carolina, the CF Foundation
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and the NIDDK (Aris 2004). Novartis Pharmaceuticals Pty Ltd,
Australia partly funded one trial (Chapman 2009). Study funding
was also provided by Merck Frosst Canada (Papaioannou 2008).
Haworth and colleagues received funding from theCFTrust in the
UK (Haworth 2001; Haworth 2011). The later Haworth study
was funded by unrestricted educational grants from Proctor &
Gamble (Norwich, USA) and the Cystic Fibrosis Trust, with sup-
port to investigators from the UK National Institute of Health
Research (Haworth 2011).
Excluded studies
Two clinical trials were excluded (Conway 2004; Hardin 2005).
One trial was a prospective open study assessing the effect of oral
bisphosphonates on BMD and body composition in adults with
CF (Conway 2004). It was not a randomised controlled trial.
The other trial assessed the effect of growth hormone on bone
mineral content in children with CF (Hardin 2005). It did not
assess the use of bisphosphonates and hence did not meet the
inclusion criteria for this review.
Risk of bias in included studies
For detailed information on the risk of bias of each included trial,
please refer to the risk of bias tables attached to the ’Characteristics
of included studies’ section of this review.
Allocation
All trials stated that allocationwas in accordance to randomisation.
One trial reported the use of a computer-generated randomisation
code, stratified according to institution (prepared by an indepen-
dent randomisation centre) with use of block allocation to en-
sure equitable distribution to each treatment group (Papaioannou
2008). In another trial, participants were allocated to treatment
or placebo using a computer programme to minimise differences
between groups in treatment centre, sex and baseline lumbar spine
BMD (Haworth 2011). We judged these two trials to have a low
risk of bias. Two trials described a “blocks of four” design, but the
actual method of randomisation was not discussed. We judged the
risk of bias due to the generation of the randomisation sequence
as unclear (Aris 2000; Aris 2004). In the other trials, the method
of randomisation and hence the risk of bias was unclear (Boyle
2005; Chapman 2009; Haworth 2001).
Concealment of allocation and hence risk of bias was low in two
trials (Haworth 2011; Papaioannou 2008) and unclear in the re-
maining five trials (Aris 2000; Aris 2004; Boyle 2005; Chapman
2009; Haworth 2001).
Blinding
Clinician or person delivering treatment
In one trial, clinicians giving the interventions were not blinded
(Aris 2000) and thus risk of bias was high and in another, this was
not reported (Haworth 2001). Three trials were described as “dou-
ble-blind”, but the blinding of those delivering treatment was not
specifically discussed (Aris 2004; Boyle 2005; Chapman 2009). In
another trial, blinding was not reported (Haworth 2001). Hence,
these four trials were judged to have an unclear risk of bias. Clini-
cians delivering treatment were blinded in two trials, leading us to
judge them to have a low risk of bias (Papaioannou 2008;Haworth
2011).
Participants
In one trial, participants were not blinded to the treatment group
(Aris 2000) (thus a high risk of bias) and in another trial, this was
not reported leading to an unclear risk of bias (Haworth 2001).
Participants were blinded to the intervention group in the other
five trials, which we therefore judged to have a low risk of bias (Aris
2004; Boyle 2005; Chapman 2009; Haworth 2011; Papaioannou
2008).
Outcome assessors
In one trial, only the radiologist who interpreted the DXA scans
was blinded (Aris 2000). In the Chapman trial, it was stated that
the personnel who performed and analysed the DXA scans were
blinded to the treatment group, but it was not clear whether all
the outcome assessors were blinded (Chapman 2009). In one trial,
blinding was not reported (Haworth 2001) and two other trials
were described as “double-blind” although it was not specifically
discussed whether all the outcome assessors were blinded (Aris
2004; Boyle 2005).
Hence considering these different types of participants and per-
sonnel together, there was some risk of bias in five of the trials (Aris
2000; Aris 2004; Boyle 2005; Chapman 2009; Haworth 2001).
Person(s) responsible for participants care, participants and out-
come assessors were blinded to treatment group allocation in the
trial by Papaioannou (Papaioannou 2008). In the later Haworth
trial, only the study pharmacist had access to the treatment alloca-
tion (Haworth 2011). Hence there was a low risk of bias in these
trials (Haworth 2011; Papaioannou 2008).
Incomplete outcome data
All seven trials described withdrawals from treatment. Further de-
tails can be found in the ’Risk of bias’ tables in Characteristics
of included studies (Aris 2000; Aris 2004; Boyle 2005; Chapman
2009; Haworth 2001; Haworth 2011; Papaioannou 2008).
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In one trial, five withdrawals between commencement of protocol
and outcomes measured at six months were described, but not
delineated as to whether they were in the treatment or the control
group (Aris 2004). In the earlier Aris trial, it was described that
three participants died during the course of the study before the
first primary end-point measurement (causes of death were one
each from sepsis, acute respiratory distress syndrome and oblit-
erative bronchiolitis). These participants were excluded from the
final analysis of baseline characteristics and outcome data. How-
ever, it was not reported which treatment group they were in (Aris
2000). Hence the risk of bias was unclear for both these trials. In
another trial, it was unclear which specific participants had BMD
measurements available at each time-point, particularly for fore-
arm measures (fewer measurements compared with lumbar spine
and femoral neck) (Chapman 2009).
In the trial by Boyle, 40 participants were planned for enrolment
but only five enrolled (three in treatment group) before the study
was stopped by the Data and Safety Monitoring Board after three
participants experienced adverse effects. It was assumed that the
three patientswith bone painwere in the treatment group although
this was not stated, hence was judged to be low risk of bias (Boyle
2005). Details of withdrawals were provided by the author for one
study i.e. unpublished data (Haworth 2011) thus judged as low
risk of bias. Two other trials were also judged as low risk (Haworth
2001; Papaioannou 2008).
Withdrawal rates and hence risk of attrition bias varied. For exam-
ple, from protocol commencement to BMD (lumbar spine) mea-
surement at end of study, total withdrawals were 0/34 (0%) (Aris
2000),13/53 (25%) (Aris 2004), 3/22 (14%) (Chapman 2009),
3/31 (10%) (Haworth 2001), 12/36 (33.3%) (Haworth 2011),
8/56 (14.2%) (Papaioannou 2008) and 3/5 (60%) (Boyle 2005).
Selective reporting
Outcome measures described in the methodology were reported
for most trials, hence we judged them to have a low risk of
bias (Aris 2004; Chapman 2009; Haworth 2001; Haworth 2011;
Papaioannou 2008). The exception was the serum and urine bio-
chemical measurements at the two-day time-point (only after first
pamidronate infusion in intervention group) which were not re-
ported in one trial (Aris 2000). The remaining trial was only pub-
lished as an abstract with insufficient detail to allow us to make a
judgement on this domain (unclear risk of bias) (Boyle 2005).
Other potential sources of bias
There were other potential sources of bias in three trials (Aris 2004;
Boyle 2005; Haworth 2001). One trial was designed to be two
years in length, but few participants were willing to consent to
such a lengthy study, so the protocol was revised to measure the
primary endpoint at 12 months (Aris 2004). Another trial dura-
tion was planned for one year, but was shortened to six months
because of adverse events (Haworth 2001). In the third trial, the
study was stopped by its Data and Safety Monitoring Board af-
ter three participants experienced dramatic musculoskeletal pain,
two requiring emergency room assessment. Symptoms began six
to eight hours after infusion, peaked at 12 to 18 hours, and were
characterized by severe chest and back pain. Along with muscu-
loskeletal pain, one participant also experienced a fever of 104°F
lasting for several hours and a rise in Tumour Necrosis Factor-
α. Although the most severe symptoms resolved within 48 to 72
hours, participants reported continued arthralgias for up to a week
(Boyle 2005).
Effects of interventions
Seven trials were included, six examined participants who had
not undergone lung transplantation (Aris 2004; Boyle 2005;
Chapman 2009; Haworth 2001; Haworth 2011; Papaioannou
2008); the other studied participants received lung transplants
(Aris 2000). All participants were adults.
Trials of participants who have not received lung
transplant
Primary outcome
1. New fractures
Combining data from three trials for vertebral fractures at the 12-
month time-point; there were no vertebral fractures reported for
either group (20 participants in each) in the trial assessing 10 mg
daily of oral alendronate (Aris 2004) or for either group (10 par-
ticipants in each) in the trial assessing intravenous zolendrate ev-
ery three months (Chapman 2009). However, there were two new
vertebral fractures in the control group (24 participants) compared
to none in the 23 participants in the group receiving 70 mg weekly
of oral alendronate (Papaioannou 2008). Hence, there was no sta-
tistically significant difference in the number of participants with
new non-vertebral fractures in the treatment group compared to
controls after 12 months of intervention, OR 0.19 (95% CI 0.01
to 4.21) (Analysis 1.1). At the 24-month time-point, data from
two trials did not show any vertebral fractures in either treatment
or control group (Chapman 2009; Haworth 2011) (Analysis 1.1).
Data from the two trials which reported non-vertebral fractures
at 12 months were combined (Aris 2004; Chapman 2009). There
was no statistically significant difference in the number of partic-
ipants with new non-vertebral fractures in the treatment group
compared to controls, OR 2.11 (95% CI 0.18 to 25.35) (Analysis
1.2). In the Aris trial, 2 out of 20 participants in the alendronate
group reported fractures (arm and rib) compared to 1 out of 20
participants in the control group (toe fracture) (Aris 2004); there
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were no reported fractures in the Chapman trial (Chapman 2009).
Neither did Chapman report any fractures in either group at 24
months (Chapman 2009). Similarly, there were no non-vertebral
fractures in either group with the intervention of 35 mg weekly of
oral risedronate for 24 months (Haworth 2011).
Combining data for both vertebral and non-vertebral fractures
from the available studies, there was no significant difference be-
tween groups at 12 months, OR 0.72 (95% CI 0.13 to 3.80) and
no fractures reported at 24 months (Analysis 1.3).
Fractures were not reported as an outcome measure in the other
two trials. We contacted the authors to clarify if these had been
measured in the trials, but did not receive a reply (Boyle 2005;
Haworth 2001).
Secondary outcomes
1. Per cent change in BMD
a. Lumbar spine
We have presented individual time-points (Analysis 1.4) and sum-
mary end of study data (Analysis 1.5).
All six studies reported on this outcome (Aris 2004; Boyle 2005;
Chapman 2009; Haworth 2001; Haworth 2011; Papaioannou
2008).
At the six-month time-point, data from the four studies showed
there was a significant increase in BMD measured at the lum-
bar spine in the treatment group, MD 4.61 (95% CI 3.90 to
5.32) (Aris 2004; Boyle 2005; Chapman 2009; Haworth 2001)
(Analysis 1.4). In the study by Aris, participants receiving oral al-
endronate had increased lumbar spine BMD after six months of
the intervention; lumbar spine BMD decreased in control group
participants at this time-point (Aris 2004). The MD for per cent
change BMD at the lumbar spine after six months was 5.50 (95%
CI 4.11 to 6.89) (Aris 2004). The Boyle trial was ceased after
only five participants were enrolled (three in the treatment group).
The mean (SD) lumbar spine BMD had increased by mean (SD)
4.7 (0.6)% six months after the single dose of intravenous zole-
dronate compared to no change in the two participants in the
placebo group (Boyle 2005). In the second study, intravenous zole-
dronate was associated with a statistically significant positive ef-
fect on BMD at the lumbar spine after six months of treatment,
MD 4.16 (95% CI 3.30 to 5.02) (Chapman 2009). In the Ha-
worth study, after six months intravenous pamidronate interven-
tion, participants in the control group had decreased lumbar spine
BMD; participants in the treatment group had gained BMD in
this region, MD for per cent change lumbar spine BMD at six
months was 5.80 (95% CI 2.91 to 8.69) (Haworth 2001). There
was low statistical heterogeneity between studies; I2 = 39% at the
six-month time-point.
Four studies had data available at the 12-month time-point
(Aris 2004; Chapman 2009; Haworth 2011; Papaioannou 2008)
(Analysis 1.4). These combined data showed a significant increase
in BMD in favour of bisphosphonates, MD 6.10 (95% CI 5.10 to
7.10). In the study byAris, participants in the treatment group had
increased lumbar spine BMD after 12 months of the intervention.
This decreased in control group participants at this time-point,
MD 6.70 (95% CI 4.51 to 8.89) (Aris 2004). In the Chapman
study, the intervention showed a statistically significant positive
effect on BMD at the lumbar spine after 12 months of treatment,
MD 6.25 (95% CI 4.88 to 7.62) (Chapman 2009). The other
studies also showed a significant increase in BMD at the lumbar
spine with MD 5.50 (95% CI 0.61 to 10.39) for the oral rise-
dronate trial (Haworth 2011) and MD 5.28 (95% CI 3.13 to
7.43) for the second oral alendronate trial (Papaioannou 2008).
At this 12-month time point, there was also low statistical hetero-
geneity between studies; I2 = 0% (Analysis 1.4).
Data for lumbar spine BMD at the 24-month time-point were
reported by two trials and this result, too, was significant in favour
of the treatment group,MD5.49 (95%CI 4.38 to 6.60), although
only one trial showed a statistically significant positive effect of
bisphosphonates withMD5.70 (95%CI 4.55 to 6.85) (Chapman
2009) compared withMD3.00 (95%CI -0.95 to 6.95) (Haworth
2011); for this time-point I2 = 40% (Analysis 1.4).
Pooling end of study results for trials assessing bisphosphonates,
there were positive BMD effects at the lumbar spine, MD 5.67
(95% CI 4.81 to 6.53) (Analysis 1.5). There was no statistical
heterogeneity between studies for lumbar spine BMD (I2 = 0%)
(Aris 2004; Boyle 2005;Chapman 2009;Haworth 2001;Haworth
2011; Papaioannou 2008).
b. Total hip or femur
Five studies reported on this outcome (Aris 2004; Chapman 2009;
Haworth 2001; Haworth 2011; Papaioannou 2008). We have
presented individual time-points (Analysis 1.6) and summary end
of study data (Analysis 1.7).
Combined data at six months showed a significant result in favour
of bisphosphonates for total hip or femur BMD, MD 3.35 (95%
CI1.63 to 5.07) (Analysis 1.6). In theAris trial, participants receiv-
ing oral alendronate had increased total hip or femur BMD after
six months of the intervention; but this outcome was unchanged
in the control group at this time, MD 2.20 (95% CI 0.81 to 3.59)
(Aris 2004). Chapman reported that intravenous zoledronate was
associated with a statistically significant positive effect on BMD at
the total hip or femur regions after six months of treatment, MD
4.63 (95% CI 3.49 to 5.77) (Chapman 2009). In the earlier Ha-
worth trial, after the six months intravenous pamidronate inter-
vention, participants in the control group had decreased total hip
or femur BMD; participants in the treatment group had gained
BMD in this region, MD 3.00 (95% CI 0.60 to 5.40) (Haworth
2001).
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Data from four trials were combined at the 12-month time-point
and showed a significant increase in total hip or femur BMD,MD
4.35 (95% 2.99 to 5.70) (Aris 2004; Chapman 2009; Haworth
2011; Papaioannou 2008) (Analysis 1.6). At 12 months, partic-
ipants in the Aris trial receiving oral alendronate had increased
total hip or femur BMD but this decreased compared to base-
line in the control group, MD 3.50 (95% CI 1.01 to 5.99) (Aris
2004). Chapman reported a statistically significant positive effect
on BMD at the total hip or femur regions in the zolendrate group
after 12 months of treatment, MD 5.71 (95% CI 4.25 to 7.17)
(Chapman 2009). Papaioannou also showed a significant increase
in BMD at the total hip or femoral neck with MD 3.44 (95% CI
1.72 to 5.16) (Papaioannou 2008). The trial assessing oral rise-
dronate did not show a significant increase in BMD at this site at
12 months, MD 3.80 (95% CI -0.43 to 8.03) (Haworth 2011).
At the 24-month time-point, the two studies were also significant
in favour of the intervention, MD 6.05 (CI 95% 3.74 to 8.36)
(Chapman 2009; Haworth 2011) (Analysis 1.6).
Pooling end of study results for all bisphosphonates, there were
positive BMD effects at the total hip or femur, MD 4.29 (95%
CI 2.45 to 6.13) (Analysis 1.7).
There was substantial heterogeneity between studies for total hip
or femur (I2 = 73% at six months) and (I2 = 74% for end of
study). At the 12-month and 24-month time points, there was
low statistical heterogeneity between studies; I2 = 38% and 39%
respectively.
c. Radius
Please refer to Analysis 1.8, Analysis 1.9 and Analysis 1.10.
Two studies reported data for distal radius (Chapman 2009;
Haworth 2001) and one reported data for ultra distal radius
(Haworth 2001).
Combined data for distal radius at the six-month time-point do
not show a significant result, MD -0.49 (95% CI -2.42 to 1.45).
In the Chapman study, distal radial BMD was not statistically
different from the control group at six months, MD 0.32 (95%CI
-0.50 to 1.14). In the Haworth study, there was a non-significant
decrease in BMD as measured by SXA of the distal forearm, MD
-1.70 (95% CI -3.66 to 0.26) (Analysis 1.8).
Only Chapman reported data for the 12-month and 24-month
time-points. At 12 months, distal radial BMDwas not statistically
different from the control group, MD 0.32 (95% CI -0.30 to
0.94). However, at 24 months, this was significant in favour of
bisphosphonates, MD 1.50 (95% CI 0.41 to 2.59) (Chapman
2009) (Analysis 1.8).
Pooling end of study results, there was no significant change in
BMD at the distal forearm, MD 0.01 (95% CI -3.12 to -3.14)
(Chapman 2009; Haworth 2001) (Analysis 1.9).
As is the case for total hip or femur, there was substantial statistical
heterogeneity between studies for distal radius (I2 = 71% at 6
months).
In theHaworth study, measurements of appendicular sites showed
opposite trends. There was a non-significant decrease in BMD
as measured by SXA of the ultra distal forearm in participants
receiving pamidronate at six months, MD -2.70 (95% CI -5.59
to 0.19) (Haworth 2001) (Analysis 1.10).
2. Quality of life
No quality of life measurements were reported in five of the trials
(Aris 2004; Boyle 2005;Chapman 2009;Haworth 2001;Haworth
2011). One trial of oral alendronate assessed mean changes over
12 months using the physical component score and mental com-
ponent score of the Medical Outcomes Study 36-item short form,
version 2 (SF-36v2) (Papaioannou 2008) (Analysis 1.11). There
was no significant change in the physical component score, MD
2.51 (95%CI -1.38 to 6.40); mental component score, MD -5.93
(95% CI -11.73 to -0.13); and total score MD -0.11 (95% CI -
3.35 to 3.12).
3. Adverse events
Six studies reported on adverse events (Aris 2004; Boyle 2005;
Chapman 2009; Haworth 2001; Haworth 2011; Papaioannou
2008).
We were able to present combined data in a meta-analysis for bone
pain (Analysis 1.12), fever (Analysis 1.13) and information on
gastrointestinal adverse effects. For this outcome information was
not available per patient for all studies, so has been presented nar-
ratively. If the required information from the study investigators
becomes available, a meta-analysis will be performed for a future
update of the review.
a. Bone Pain
In one study of oral alendronate for 12 months, none of the par-
ticipants in either the intervention or the control group experi-
enced bone pain (Aris 2004). The other study also assessing oral
alendronate for 12 months did not report bone pain in any partic-
ipants; three of the participants in the treatment group used oral
corticosteroids with the mean yearly cumulative dose 49.32 mg
(Papaioannou 2008). In the 24-month trial of oral risedronate,
four participants withdrew completely due to bone pain (three in
the first 12 months) and one participant discontinued the study
medicationdue to bone pain.TheHaworth trial of oral risedronate
reported that bone pain was recorded 19 times by nine different
risedronate patients in the first year after randomisation, while
there were no episodes of bone pain in the placebo group, OR
43.59 (95% CI 2.27 to 837.56). Fourteen of 19 (74%) episodes
occurred within the first 56 days after randomisation. Five events
(26%) were classified as severe and led to the discontinuation of
the study medication. Of the other events, ten were classified as
12Bisphosphonates for osteoporosis in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
moderate and four as mild. Only two (11%) events were consid-
ered to be unrelated to the study medication. Bone pain usually
started within 24 hours of the first dose of risedronate and lasted
for approximately 72 hours (Haworth 2011).
Pooling the results for intravenous bisphosphonates, including the
study in which participants received oral prednisone daily for three
days on themorning of the first infusion (repeatedwith subsequent
infusions if a reaction to the first infusion was thought likely), the
occurrence of bone pain was significantly higher in participants in
the treatment groups (18 out of 28) compared to control groups
(2 out of 32), OR 14.17 (95% CI 3.64 to 55.17) (Boyle 2005;
Chapman 2009;Haworth 2001). Boyle reported that three partic-
ipants experienced dramatic musculoskeletal pain, two requiring
emergency room assessment. Symptoms began six to eight hours
after infusion, peaked at 12 to 18 hours, and were characterized by
severe chest and back pain. Although the most severe symptoms
resolved within 48 to 72 hours, participants reported continued
arthralgias for up to a week. It was presumed that these three par-
ticipants were those in the treatment group (no reply was received
to an attempt to contact the author) (Boyle 2005). Chapman re-
ported that there was no significant difference between treatment
and control groups with respect to musculoskeletal pain (4 out of
10 in the zoledronate group, 2 out of 12 in the control group),
OR 3.33 (95% CI 0.46 to 24.05) (Chapman 2009). In the Ha-
worth 2001 trial, no participants in the control group experienced
bone pain; but 11 out of 15 participants in the treatment group
experienced moderate to severe pain following the first dose of
medication, OR 94.56 (95% CI 4.65 to 1924.08). Nine partic-
ipants reported severe bone pain. The pain was reported to be
excruciating in seven participants rendering them bed bound and
making sputum expectoration and physiotherapy difficult. None
of the participants experiencing bone pain were taking corticos-
teroids, while three of the four participants without bone pain in
the treatment group did (Haworth 2001).
Combining study results for all routes of administration, bispho-
sphonates were associated with significantly higher occurrence
of bone pain, OR 18.52 (95% CI 5.39 to 63.57) (Aris 2004;
Boyle 2005; Chapman 2009; Haworth 2001; Haworth 2011;
Papaioannou 2008).
b. Fever
In the 12-month study of oral alendronate, none of the participants
in either the intervention or the control group experienced fever
(Aris 2004). In the other trials of oral bisphosphonates, it was not
stated that fever was one of the adverse events that were reported
(Haworth 2011; Papaioannou 2008).
Combined data from the trials of intravenous bisphosphonates
show participants in the treatment groups were significantly more
likely to experience fever,OR12.64 (95%CI2.31 to 69.11) (Boyle
2005; Chapman 2009; Haworth 2001). Boyle reported that one
participant experienced a fever of 104°F lasting for several hours
and a rise in Tumour Necrosis Factor-α, OR 3.00 (95%CI 0.08 to
115.34) (Boyle 2005). In the Chapman trial the number of partic-
ipants experiencing fever was significantly higher in the treatment
group (8 out of 10 in the zoledronate group, 1 out of 12 in the
control group), OR 44.00 (95% CI 3.38 to 573.41) (Chapman
2009). Haworth reported that two of the nine participants in the
treatment group had febrile reactions, OR 6.74 (95% CI 0.29 to
154.26) (Haworth 2001).
c. Gastrointestinal adverse effects
Gastrointestinal adverse effects were described in the trials assess-
ing oral bisphosphonates (Aris 2004;Haworth 2011; Papaioannou
2008). In the Aris study, three cases of diarrhoea were reported;
one participant was receiving alendronate and two were receiv-
ing placebo. This was accompanied by abdominal cramping and
loss of appetite. These participants continued to experience diar-
rhoea after discontinuing the study medication. One participant
reported dysphagia but it was not clear which study group they
were in (Aris 2004). In Papaioannau’s trial of oral alendronate,
there were 10 gastrointestinal-related adverse events in the treat-
ment group (three events of nausea or vomiting or both and one
event of each of reflux, difficulty swallowing, oesophagitis, consti-
pation, gastrointestinal upset, intestinal obstruction and stomach
pain or burn). There were seven gastrointestinal-related adverse
events in the control group (four events of nausea or vomiting or
both and one event of each of constipation, intestinal obstruction
and stomach pain or burn) (Papaioannou 2008). Gastrointestinal
symptoms were also reported in the oral risedronate trial (26 in
the treatment group and 16 in the placebo group). These events
corresponded to the same number of participants in each study
group (nine in risedronate, nine in placebo) (Haworth 2011).
d. Other adverse effects
Chapman reported that musculoskeletal side effects were experi-
enced following 27 of 63 zoledronate infusions, but after only 4 of
73 placebo infusions. This was despite administering prednisolone
to all participants with at least the first infusion, and these side
effects were more common after the first than the subsequent in-
fusions. In six participants, the reactions were described as severe,
in two cases resulting in withdrawal. One of these participants re-
quired admission to hospital with severe pain and fever restricting
movement, with onset 12 hours after the first infusion; this re-
solved after four days, but led to subsequent withdrawal from the
study. The other participant experienced fever, rigor, bone pain
and headache 24 hours after the first infusion with resolution in
five days. Similar effects were experienced after the second infu-
sion followed by study withdrawal (Chapman 2009).
In the 24-month trial of oral risedronate, two participants discon-
tinued the study medication in the first 12 months due to muscle
aches or generalised pain. Within two years of randomisation 346
adverse events were recorded; most events were classed as respira-
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tory exacerbations (n = 230) and it was stated that there was no
difference in incidence between the two groups (Haworth 2011).
In the earlier Haworth trial, it was reported that one participant
developed phlebitis around the infusion site (Haworth 2001).
Papaionnou reported serious adverse events in the alendronate
group as exacerbation of CF (n = 3), bronchial superinfection (n
= 1), hypoglycaemic seizure (n = 1), gastrointestinal obstruction
(n = 1) and intestinal obstruction (n = 1). Serious adverse events
reported for the control group included an exacerbation of CF
(n = 3), with two of these participants experiencing additional
gastrointestinal complaints (Papaioannou 2008).
None of the studies assessed calcium levels post-intravenous bis-
phosphonate infusion (Boyle 2005; Chapman 2009; Haworth
2001).
4. Withdrawals
We have presented data for withdrawals due to adverse events
(Analysis 1.14) and total withdrawals (Analysis 1.15).
Five studies described withdrawals from the study. At 12 and 24
months, there were significantly more withdrawals due to adverse
events in the treatment group compared to the control group, OR
4.07 (95% CI 1.11 to 14.90) and 16.34 (95% CI 1.98 to 134.89)
respectively. At 6, 12 and 24 months, data from these trials do
not show any significant difference between treatment or control
groups for total withdrawals for any reason (Aris 2004; Chapman
2009; Haworth 2001; Haworth 2011; Papaioannou 2008).
In the Aris study, of the 53 participants who started the protocol,
five dropped out in the first six months. The reasons included
pregnancy (n = 1, experienced a spontaneous abortion in her first
trimester), dysphagia (n = 1, experienced difficulty swallowing the
first tablet and had similar difficulties swallowing other medica-
tions), and diarrhoea (n = 3). For the first two participants, it was
unclear which group they were allocated to. One of the partici-
pants experiencing diarrhoea was receiving alendronate and two
were receiving placebo. No participants withdrew due to gastroin-
testinal reflux symptoms. Of the 48 participants who completed
DXA assessment at sixmonths beyond baseline, 4 out of 24 in each
group withdrew before the DXA assessment at 12 months beyond
baseline. In the treatment group, the withdrawals were due to lung
transplantation (n = 1), moving (n = 2) and non-compliance (n =
1); in the control group these were due to lung transplantation (n
= 2), death (n = 1) and moving (n = 1) (Aris 2004).
In the first 12 months of the later Haworth trial, 3 out of 17 in the
oral risedronate group withdrew from the study completely (due
to bone pain) and three patients discontinued the study medica-
tion (one citing bone pain and the other two participants citing
muscle aches or generalised pain) but remained in the study for
follow up. Between 12 and 24 months one further participant
withdrew from the intervention group (citing bone pain). At 24
months, 12 participants remained in study with nine still taking
the study drug. Immediately after randomisation one participant
in the placebo group withdrew consent before taking the study
medication. Therefore, only 18 participants were commenced on
placebo. By 12 months, two participants in the placebo group
withdrew consent and one participant had died. By 24 months,
three participants in the placebo group had withdrawn consent
and four patients had died, hence at 24 months, 12 participants
remained in the control group of the study. In the 24 months
there was no significant difference between groups with respect
to total withdrawals (8 of 17 in the risedronate group ceased the
medication, 7 out of 19 in the control group), OR 1.52 (95% CI
0.40 to 5.78) (Haworth 2011).
In the 12-month trial by Papaioannou, 4 of 27 in the oral alen-
dronate group withdrew (one due to an adverse event, one with-
drew consent and two due to non-compliance). In the placebo
group, 5 of 29 withdrew (two due to non-compliance, two due
to an adverse event and one was lost to follow-up) (Papaioannou
2008).
At 24months,Chapman reports therewas no significant difference
between intravenous zoledronate and control with respect to total
withdrawals (3 out of 10 in the treatment group, 6 out of 12 in the
control group), OR 0.43 (95% CI 0.07 to 2.50) or withdrawals
due to adverse events (2 out of 10 in the treatment group, 0 of 12
in the treatment group), OR 7.35 (0.31 to 173.13). The adverse
events have been described previously. The withdrawal that was
unrelated to adverse events in the treatment group was due to loss
to follow-up. The six withdrawals in the control group were due to
loss to follow-up (n = 1), decreased BMD to withdrawal threshold
(n = 3), poor compliance to study requirements (n = 1) and a
combination of the latter two reasons (n = 1) (Chapman 2009).
Haworth also reports no significant difference between intra-
venous pamidronate and control groups with respect to total with-
drawals over the sixmonths (2 out of 15 in the pamidronate group,
1 out of 16 in the control group), OR 2.31 (95% CI 0.19 to
28.47). One participant from each group died, while a second
participant in the pamidronate group withdrew in order to receive
a double lung transplant. No participant withdrew due to other
adverse events (Haworth 2001).
5. Survival
We have presented data on this outcome in the graphs (Analysis
1.16).
Of the 48 participants in the oral alendronate trial who completed
DXA assessment at six months beyond baseline, one participant
out of 24 in the control group died during the latter six months
of the study compared to none in the treatment group. This dif-
ference was not statistically significant, OR 3.13 (95% CI 0.12
to 80.68) (Aris 2004). Combining this survival data with the 12-
month outcome data of the oral risedronate trial did not show
a statistically significant difference, OR 2.98 (95% CI 0.30 to
29.84) (Aris 2004; Haworth 2011).
Three of the trials reported there were no deaths in either the treat-
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ment or control group (Boyle 2005; Chapman 2009; Papaioannou
2008).
Haworth reported that intravenous pamidronate treatment for a
duration of six months did not significantly affect survival com-
pared with the control group (14 out of 15 survivors in the
pamidronate group, 15 out of 16 in the control group), OR 0.93
(95% CI 0.05 to 16.39) (Haworth 2001).
Haworth also reported that oral risedronate treatment for 24
months did not significantly affect survival compared with the
control group (16 out of 17 survivors in the risedronate group,
15 out of 19 in the control group), 4.27 (95% CI 0.43 to 42.63)
(Haworth 2011).
Trial of participants who have received lung transplant
Only one trial reported on this comparison (Aris 2000).
Primary outcome
1. New fractures
There was no statistically significant difference in the number of
participants with new vertebral fractures in the bisphosphonate
(pamidronate) group (3 out of 16 participants) versus the control
group (1 out of 18 participants), OR 3.92 (95%CI 0.36 to 42.20)
(Analysis 2.1). There was also no statistically significant difference
in the number of participants with new non-vertebral fractures in
the treated (3 out of 16 participants) versus the untreated group (6
out of 18 participants), OR 0.46 (95% CI 0.09 to 2.27) (Analysis
2.2). Considering any fractures, there was also a non-significant
result, OR 0.94 (95% CI 0.24 to 3.77) (Analysis 2.3).
Secondary outcomes
1. Per cent change in BMD
a. Lumbar spine
At the end of two years, the per cent change in BMD was signifi-
cantly higher in the treatment group than in the control group at
the lumbar spine, MD 6.20 (95% CI 4.28 to 8.12) (Analysis 2.4).
b. Hip or femur
Likewise, at the end of two years, the per cent change in BMD
was significantly higher in the treatment group than in the control
group at the femur, MD 7.90 (95% CI 5.78 to 10.02) (Analysis
2.5).
2. Quality of life
No quality of life measurements were reported (Aris 2000).
3. Adverse events
None of these participants, all of whom were receiving corti-
costeroids, experienced any bone pain (Analysis 2.6). Partici-
pants were assessed 24-hours post-infusion for cellulitis, throm-
bophlebitis, or fever; no cases were detected. Twenty-four hours
later, serum calcium, phosphorus, and magnesium and a complete
blood count were analysed. The study authors reported that there
were no significant differences compared with pre-infusion data,
with no episodes of hypocalcaemia and three episodes of mild hy-
pervitaminosis D that resolved spontaneously. The trial in post-
transplant participants also reported that there was no significant
difference in the degree of immunosuppression between the treat-
ment and control groups (Aris 2000).
4. Withdrawals
There were no withdrawals other than those due to death in either
treatment group (Analysis 2.7; Analysis 2.8).
5. Survival
Three participants died before the first BMD data could be col-
lected at six months; these participants were excluded from further
analysis and thus cannot be included as data in this review. The
authors stated that the exclusion of these three participants did not
significantly affect the subsequent analysis (Aris 2000). No other
participants died during the course of the trial (Analysis 2.9).
Sensitivity analysis
a. Differences in the medications used in the intervention
and comparison groups
Considering non-transplanted participants, the differences in ad-
verse events between oral and intravenous bisphosphonates have
been described. The per cent increase in BMD at the lumbar spine
still increased significantly at six months when oral bisphospho-
nates were analysed separately to intravenous bisphosphonates;
oral bisphosphonates, MD for per cent change was 5.50 (95% CI
4.11 to 6.89) (Aris 2004), intravenous bisphosphonates, MD 4.29
(95% CI 3.47 to 5.12) (Boyle 2005; Chapman 2009; Haworth
2001). This was also observed for the effect on lumbar spine BMD
(12 months and end of study) and hip or femur BMD (6 months,
12 months, 24 months and for outcomes at the end of study).
At 24 months, only intravenous bisphosphonates significant in-
creased BMD at the lumbar spine.
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b. Analysis using random-effects model
Combining data for both vertebral and non-vertebral fractures
from the available studies, there was still no significant difference
between groups using the random-effects model, OR 0.76 (95%
CI 0.07 to 7.92) (Analysis 1.3).
Using the random-effects model, the MD results for per cent in-
creases in BMD for lumbar spine were still significant at the six-
month time-point, MD 4.81 (95% CI 3.75 to 5.88); the 12-
month time-point, MD 6.10 (95% CI 5.10 to 7.10); the 24-
month time-point, MD 5.04 (95% CI 2.76 to 7.31) and end of
study, MD 5.67 (95% CI 4.81 to 6.53) (Analysis 1.4; Analysis
1.5).
Using the random-effects model, the MD results for per cent in-
creases in BMD for total hip or femur were also still significant
at the six-month time-point, MD 3.35 (95% CI 1.63 to 5.07);
the 12-month time-point, MD 4.35 (95% CI 2.99 to 5.70); the
24-month time-point, MD 6.05 (95% CI 3.74-8.36) and end of
study, MD 4.29 (95% CI 2.45 to 6.13) (Analysis 1.6; Analysis
1.7).
c. Analysis by “treatment received”
Due to the lack of data, this was not possible.
d. Analysis by “intention-to-treat”
Due to the lack of data, this was not possible.
D I S C U S S I O N
Six studies investigated the effect of bisphosphonates in adults
with CF who had not undergone lung transplantation (Aris 2004;
Boyle 2005; Chapman 2009; Haworth 2001; Haworth 2011;
Papaioannou 2008). One study assessed this in adults with CF
who had undergone lung transplantation (Aris 2000). Oral and
intravenous bisphosphonates increased BMD in adults with CF.
However, severe bone pain and flu-like symptoms were common
with intravenous agents, especially in participants not taking glu-
cocorticoids. A reduction in fracture rate was not observed.
Oral bisphosphonates (alendronate and risedronate) were associ-
ated with increased BMD at the lumbar spine and hip or femur
regions in adults with CF who had not undergone lung trans-
plantation in the meta-analysis from three studies (Aris 2004;
Haworth 2011; Papaioannou 2008). Three trials assessing differ-
ent intravenous bisphosphonate regimens (agent, duration and
frequency) in this population group also showed improved lumbar
spine BMD (Boyle 2005; Chapman 2009; Haworth 2001). Both
trials with hip or femur BMD as a measure showed positive ef-
fects on this outcome (Chapman 2009; Haworth 2001). The two
studies that assessed radial BMD had conflicting results. Radial
BMD was significantly improved in the zoledronate study of 24-
months duration (Chapman 2009), but not in the pamidronate
study with six-months follow-up (Haworth 2001).
There was significant clinical heterogeneity between the studies
but in the majority, only low statistical heterogeneity.
Lumbar spine and hip BMD were also improved by intravenous
pamidronate in a single trial in adult CF participants post-lung
transplantation (Aris 2000).
These trials provide valuable data on two different populations;
adults with CF who have received a transplant and those who have
not. Although the inclusion criteria, duration of follow up and
the magnitude of effect were different for the trials, similar trends
for BMD effect were seen, suggesting that the beneficial effects of
oral and intravenous bisphosphonates might be generalisable to a
fairly broad population of people living with CF.
Bone mineral density is only an intermediate outcome. The more
clinically important endpoint is the occurrence of new fractures.
There was no significant effect of treatment on fractures (total,
vertebral or non-vertebral) in participants with or without lung
transplantation (Aris 2000; Aris 2004; Chapman 2009; Haworth
2011; Papaioannou 2008).
Only one trial assessed quality of life, with no significant effect
of intervention on physical or mental components of the score
(Papaioannou 2008).
Fever was not reported in association with oral bisphosphonates
(Aris 2004). Gastro-oesophageal symptoms were reported, but not
significantly increased, in the trials of oral bisphosphonates (Aris
2004; Haworth 2011; Papaioannou 2008).
Bone pain was reported in one of the three trials of oral bisphos-
phonates (Haworth 2011). Participants who did not receive cor-
ticosteroids during the clinical trial of intravenous pamidronate
were more likely to experience bone pain (Haworth 2001). The
observed relationship between the regular use of glucocorticoid
therapy and lack of bone pain may be explained by evidence that
corticosteroids suppress the release of TNF-alpha (Steer 1997),
an inflammatory cytokine known to increase bone resorption.
Haworth suggests that bone pain may be avoided by prescribing
a short course of oral corticosteroids before and at the time of
pamidronate infusion (Haworth 2001). Zoledronate, a more po-
tent bisphosphonate than pamidronate was associated with severe
musculoskeletal pain resulting in discontinuation of one trial early
in enrolment (Boyle 2005). In a subsequent study of intravenous
zoledronate, participants were prescribed daily prednisolone for
three days commencing on the day of the first infusion (and re-
peated if thought necessary with subsequent infusions). Muscu-
loskeletal pain was not significantly increased in the treatment
group. However, fever and other flu-like effects were more com-
monly reported, severe in some participants, although themajority
continued treatment. The authors proposed that a longer period
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of treatment with corticosteroids, including pre-treatment dosing
may diminish such adverse effects (Chapman 2009). A consen-
sus statement has recommended pre-treatment with oral corticos-
teroids for three to five days prior to bisphosphonate infusion,
but this has not been studied in an RCT (Aris 2005). None of
the participants in the lung-transplanted group, all of whom were
receiving corticosteroids, experienced any bone pain.
For treatment duration of 12 to 24 months, there were signifi-
cantly more withdrawals due to adverse events than in those not
receiving bisphopsphonates. There was no significant effect on
survival. The lack of significant differences in the rate of fractures,
gastrointestinal adverse effects, withdrawals or survival may relate
to the small numbers of participants involved and the short dura-
tion of the trials
The risk of bias in the trials due to blinding was judged as present
(Aris 2000; Haworth 2001), unclear (Aris 2004; Boyle 2005;
Chapman 2009) or low (Haworth 2011; Papaioannou 2008).
When participants are aware of the treatment they are receiving,
they may be more or less likely to report adverse events. The judg-
ment of individuals who collect and interpret patient data may be
affected when the assessor is aware of the treatment a participant
is receiving. Lack of blinding may result in biased results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on seven small trials, oral and intravenous bisphosphonates
cause a rapid increase in spine and hip or femoral BMD in adults
with CF. Only two trials assessed the effect on distal radial BMD,
with only the study of longer duration reporting an improvement.
Severe bone pain is common with the use of intravenous bisphos-
phonates in participantswithCFnot receiving oral corticosteroids,
and may limit tolerability. Severe bone pain was also observed in
one of three trials of oral bisphosphonates. Oral bisphosphonate
treatment did not cause increased gastrointestinal symptoms.Only
one trial assessed quality of life and did not show a benefit. These
short-term trials (maximum of two years) did not show fracture
reduction or survival benefit. Currently, no other options for the
treatment of CF-related osteoporosis have been reported in the
public domain. Thus, although bisphosphonates increase BMD,
no recommendation can be made concerning the use of bispho-
sphonates in participants with CF as an effect on fractures could
not be demonstrated.
Implications for research
This area of research would benefit from a large multicentre RCT
of bisphosphonates (oral and intravenous) with separate analyses
for participants with and without lung transplantation to mea-
sure the effectiveness of these therapies on outcomes important to
people with CF, such as fractures and survival. These outcomes
would require long-term studies. Data on adverse events such as
gastrointestinal events, bone pain and fever, in addition to the use
of corticosteroids should also be recorded. Studies assessing pre-
treatment with corticosteroids are required.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aris 2000
Methods Randomised controlled trial, parallel design.
Trial duration 2 years.
Single centre, university hospital, USA.
Participants Inclusion criteria: CF; 1 to 12 months post-lung transplantation; ambulatory.
Exclusion criteria: primary graft failure or other post-operativemorbidities that precluded
long-term survival; renal insufficiency (serum creatinine > 3.0 mg/dl); or pregnancy
Total participants: n = 34 (17 female).
Treatment group: n = 16 (7 female); mean (SD) age 27.5 years (6.6 years);
Control group: n = 18 (10 female); mean (SD) age 29.1 years (6.4 years)
Groups similar in age, gender, baseline T-scores, renal function, hospitalisation rates,
immunosuppressant levels, change in lung function and BMI over study period
13 in treatment group and 12 controls had baseline T-scores < -2.5 at a minimum of
one site; all others -1 < T < -2.5 at a minimum of one site
Interventions Treatment group: intravenous pamidronate (30 mg every 3 months) plus oral vitamin
D (800 IU/day) and oral calcium (1 g/day)
Control group: oral vitamin D (800 IU/day) and oral calcium (1 g/day)
Outcomes Primary outcome
• BMD (spine; 0, 6, 12, 18, 24 months; DXA Hologic QDR 1000/W Waltham
MA)
Secondary outcomes
• BMD femur (at 0, 6, 12, 18, 24 months; DXA Hologic QDR 1000/W Waltham
MA)
• New fractures: number of fractures during study; long bone using clinical data,
rib using posteroanterior chest radiographs, vertebral using lateral chest radiographs
• Kyphosis angles (degrees): thoracic spine curvature using lateral chest radiographs
using a modification of method of Cobb (at 0, 24 months)
• Adverse events: number during study; thrombophlebitis, cellulitis, bone pain,
fever, hypocalcaemia defined as serum calcium < 7.8 mg/dl, hypervitaminosis defined
as serum 25-hydroxyvitamin D > 55 ng/ml
• Bone biomarkers: serum osteocalcin, urine cross-linked N-telopeptides of type 1
collagen, urine free deoxypyridinoline (at 0, 3, 12, 24 months; also 2, 14 days after first
pamidronate infusion in intervention group)
• Serum calcium, vitamin D (25-hydroxyvitamin D, 1,25-dihydroxyvitamin D)
and PTH levels (at 0, 3, 12, 24 months)
• Withdrawals
• Survival
Notes 44 people with CF were eligible during the course of this study, 7 died immediately
post-operatively and were therefore not eligible for this trial. As outlined above, 3 people
died during the course of the study before the first primary end point measurement. 34
people were included in the final analyses
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Aris 2000 (Continued)
Funding was provided by grants from the CF Foundation and the Verne S. Caviness
General Center for Clinical Research
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Blocks of four” design stated (stratified on
basis of gender and severity of osteoporo-
sis using spine z score of -3.0), but actual
method of randomisation is not discussed
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Person(s) responsible for participants care
and participants were not blinded. Of out-
come assessors, only the radiologist who in-
terpreted the DXA scans was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It was described that 3 participants died
during the course of the study before
the first primary end-point measurement
(causes of death were one each from sep-
sis, acute respiratory distress syndrome and
obliterative bronchiolitis). These partici-
pants were excluded from the final analy-
sis of baseline characteristics and outcome
data. However, it was not reported which
treatment group they were in
Selective reporting (reporting bias) High risk Serum and urine biochemical measure-
ments that were measured at 2 days (only
after first pamidronate infusion in interven-
tion group) were not reported
Other bias Unclear risk None identified.
Aris 2004
Methods Randomised controlled trial; parallel design; double-blind placebo-controlled
Trial duration 1 year for primary outcome measure (trial was intended to be 2 years
duration)
Single centre, adult CF centre, USA.
Participants Inclusion criteria: CF; ambulatory; DXA showed a spine or femur T-score of -1 or less.
Exclusion criteria: primary graft failure or other post-operative morbidities that pre-
cluded long-term survival; renal insufficiency (serum creatinine >3.0 mg/dl); active up-
per gastrointestinal disease; chronic oral glucocorticoid usage (>10 mg every day); organ
transplantation; a history of bisphosphonate intolerance or use; and pregnancy
23Bisphosphonates for osteoporosis in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Aris 2004 (Continued)
101 participants consented to be screened, 86 qualified and 53 started protocol and were
randomised
Total participants: n = 48 (23 female).
Treatment group: n = 24 (9 female); mean (SD) age 28 years (7 years)
Control group: n = 24 (14 female); mean (SD) age 27 years (9 years)
At baseline, osteoporosis was found in 3 participants and osteopenia was present in 20
participants in both the treatment and control groups
Interventions Treatment group: oral alendronate (10 mg daily) plus oral vitamin D (800 IU/day) and
oral calcium carbonate (1000 mg/day)
Control group: oral vitamin D (800 IU/day) and oral calcium carbonate (1000 mg/day)
Outcomes Primary outcome
• BMD spine (at 0, 6, 12, 18, 24 months; DXA Hologic QDR 1000/W Waltham
MA, with 12 months data as primary outcome)
Secondary outcomes
• BMD femur (at 0, 6, 12, 18, 24 months; DXA Hologic QDR 1000/W Waltham
MA)
• New fractures: number of fractures during study; long bone using clinical data,
rib using posteroanterior chest radiographs, vertebral using lateral chest radiographs
• Adverse events: number during study; fever; bone pain
• Biochemical measurements: serum (parathyroid hormone, 25-hydroxyvitamin D,
1,25-dihydroxyvitamin D, osteocalcin, bone-specific ALP) and urine (cross-linked N-
telopeptides and deoxypyridinoline)
• Withdrawals
• Survival
Notes Funded by the U.S. Food and Drug administration, Merck and Co, Inc., the Clinical
Nutrition Research Unit, the Verne S. Caviness General Center for Clinical Research at
University of North Carolina, the CF Foundation and the NIDDK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Blocks of four” design stated, but actual
method of randomisation is not discussed
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as “double-blind”.
Participants: blinded.
Clinicians or persons delivering treatment:
unclear if clinicians involved in the study
and clinicians managing the medical prob-
lems of the participants were all blinded
Outcome assessors: stated that the mus-
culoskeletal radiologist who analysed base-
line and end-of-study chest radiographs for
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Aris 2004 (Continued)
fracture was blinded, not specifically stated
that other outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawals up to 6 months:
5 withdrawals in total, but not stated
whether they were in treatment or control
group, so 48 participants were evaluable.
Reasons for dropping out: pregnancy (n=1)
; diarrhoea and weight loss (n=3); dyspha-
gia (n=1). The three participants with diar-
rhoea reported abdominal cramping, loss of
appetite, and diarrhoea before the medica-
tions began that worsened during the study
but persisted after the study medications
were discontinued, one participant was on
alendronate and two on placebo
Withdrawals between 6 and 12 months:
4 withdrawals from each group were de-
scribed.
Treatment group: 4 drop-outs; reasons
were: transplanted (n = 1); moved (n = 2);
non-compliance (n = 1).
Placebo group: 4 drop-outs; reasons were:
transplanted (n = 2); died (n = 1); moved
(n = 1)
Withdrawals between 1 and 2 years
Treatment group: 9 drop-outs; reasons
were: moved (n = 2); committed to only 1
year (n = 7).
Placebo group: 7 drop-outs; reasons were:
moved (n = 1); committed to only 1 year
(n = 6)
The primary end-point measure was anal-
ysed in 40/53 (75%) participants, hence
there is a risk of attrition bias
Stated that an intention-to-treat principle
was used in the analyses of the treatment
endpoints
Selective reporting (reporting bias) Low risk Outcome measures that were described in
the methods section were reported in the
results section
Other bias High risk Described that protocol was originally de-
signed to be 2 years in length, but few par-
ticipants were willing to consent to such
a lengthy study, so protocol was revised
to measure the primary endpoint at 12
months
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Boyle 2005
Methods Randomised, double-blinded, placebo-controlled trial; parallel design
Trial duration 6 months (originally intended for 12 months).
Participants Inclusion criteria: CF; osteopenia of the lumbar spine (T-scores -1.0 to -2.5); serum 25-
hydroxyvitamin D levels ≥ 20ng/ml prior to infusion.
Exclusion criteria: existing osteoporosis, prior treatment with bisphosphonates or previ-
ous lung transplant
N = 40 planned for enrolment but only 5 enrolled (3 in treatment group) before study
stopped by Data and Safety Monitoring Board (see notes)
Interventions Treatment group: intravenous zoledronate, 5 mg infusion administered on a single oc-
casion over 20 minutes plus supplemental oral vitamin D (800 IU) and oral calcium
(1000 mg) daily
Control group: supplemental oral vitamin D (800 IU) and oral calcium (1000 mg) daily
Outcomes • BMD lumbar spine (at 0, 6 months (originally planned additionally for 12
month))
• Change from baseline in serum C-telopeptides (at 3, 6 months (originally
planned additionally for 9 and 12 months))
Notes The study was stopped by its Data and Safety Monitoring Board after 3 participants
experienced dramatic musculoskeletal pain, 2 requiring emergency room assessment.
Symptoms began 6 to 8 hours after infusion, peaked at 12 to 18 hours, and were charac-
terized by severe chest and back pain. Along with musculoskeletal pain, one participant
also experienced a fever of 104°F lasting for several hours and a rise in tumour necrosis
factor-α. Although the most severe symptoms resolved within 48 to 72 hours, partici-
pants reported continued arthralgias for up to a week
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but process not
reported.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as ’double-blind’.
Participants: blinded.
Not discussed if clinicians or persons deliv-
ering treatment and outcome assessors were
both blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Based on interpretation of data, we have
presumed that the 3 participants who had
severe bone painwere the 3 in the treatment
group. Clarification from the author was
requested but not received
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Boyle 2005 (Continued)
Selective reporting (reporting bias) Unclear risk Abstract only but outcome measures were
described in the results
Other bias High risk The study was stopped by its Data and
Safety Monitoring Board after 3 partici-
pants experienced dramatic musculoskele-
tal pain, 2 requiring emergency room as-
sessment. Symptoms began 6 to 8 hours af-
ter infusion, peaked at 12 to 18 hours, and
were characterized by severe chest and back
pain. Along withmusculoskeletal pain, one
participant also experienced a fever of 104
oF lasting for several hours and a rise in
Tumour Necrosis Factor-α. Although the
most severe symptoms resolved within 48
to 72 hours, participants reported contin-
ued arthralgias for up to a week
Chapman 2009
Methods Randomised, double-blinded, placebo-controlled trial; parallel design
Trial duration 24 months.
Multicentre, 2 sites, CF clinics, Australia.
Participants Inclusion criteria: CF (diagnosis previously made by sweat chloride test and an appropri-
ate CF phenotype); ≥ 18 years; bone density T-score <-1.5 in at least one of three sites
(hip (femoral neck), lumbar spine 2 to 4 (L2 to L4) and distal forearm) in the month
before study commencement
Exclusion criteria: pre-existing, symptomatic, fragility fractures; untreated hyperthy-
roidism, primary hyperparathyroidism or hypogonadism; bisphosphonate treatment in
the three months before starting the study; serum calcium concentration below the lower
limit of the laboratory normal range; serum creatinine concentration more than 1.5
times the upper limit of the laboratory normal range; serum ALT, ALP or bilirubin more
than 3 times the upper limit of the laboratory normal range; on the waiting list for lung
transplantation; pregnant or lactating; considered unlikely to complete the study
Total participants: n = 22 (5 females). Age range over all: males 21 to 47 years, females
19 to 28 years
Treatment group: n = 10 (3 female); mean (SD) age 30.1 (2.2) years
Control group: n = 12 (2 females) mean (SD) age 28.6 (2.4) years
Interventions Treatment group: intravenous zoledronic acid (zoledronate) in 100 ml of normal saline
infused over 15 minutes every 3months for 21 months (8 infusions in total). For 5 out of
63 doses, 4 mg zoledronate was administered, then dose reduced to 2 mg for subsequent
doses (due to febrile reactions to the higher dose in several participants)
Placebo group: 100 ml normal saline as above.
All participants were prescribed calcium carbonate 600mg and vitaminD21000 IU each
twice daily at least 3 days before the first treatment infusion and continued throughout
the study. All participants were prescribed oral prednisolone 25mg/day for 3 days starting
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Chapman 2009 (Continued)
on the morning of the first infusion; repeated with subsequent infusions if a reaction to
the first infusion was thought likely. If there were side effects of the study infusion that
were considered to be possibly due to the infusion during the first or any subsequent
infusion, at the discretion of the investigator and participant, oral analgesia (paracetamol)
was also administered for subsequent infusions
Outcomes • Bone density at hip (femoral neck), lumbar spine (L2 - L4) and distal forearm (at
baseline, 6, 12 and 24 months)
• Plain x-rays of thoracic and lumbar spine (at baseline and 24 months (additional
films taken as indicated to confirm any suspected fractures))
• Biochemical measurements: urea; creatinine; ALP; ALT; bilirubin; calcium
(corrected); calcium (ionised); phosphate; 25-hydroxyvitamin D; PTH; complete blood
count and differential (at baseline and 2 weeks before the 6, 12, 18 and 24 months)
Notes Novartis Pharmaceuticals Pty Ltd, Australia partly funded this trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but process not
discussed.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as ’double-blind’.
Participants: blinded.
Outcome assessors: DXA scans were per-
formed and analysed by personnel blinded
to treatment assignment
Not specifically discussed if clinicians or
persons delivering treatment andother out-
come assessors were all blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals described and equal across
groups - therewere 3/10 in treatment group
and 5/12 in control group
In the treatment group, 2participantswith-
drew due to side-effects, 1 due to psychi-
atric illness
In the placebo group, one participant was
lost to follow-up, one participant’s BMD
decreased to withdrawal threshold, 2 par-
ticipants were poorly compliant to study
protocols and in one participant, both
of the latter two reasons were applica-
ble. However, it was unclear which spe-
cific participants had BMD measurements
available at each time-point, particularly
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for forearm measures (fewer measurements
compared with lumbar spine and femoral
neck)
Selective reporting (reporting bias) Low risk Outcome measures that were described in
the methods section were reported in the
results section
Other bias Low risk None identified.
Haworth 2001
Methods Randomised controlled trial; parallel design.
Trial duration planned for 1 year, but was shortened to 6 months because of adverse
events
Single centre, UK.
Participants Inclusion criteria: CF; no organ transplantation; 70% of all eligible participants in a
longitudinal BMD study recruited after one year of follow-up; no prior treatment with
bone-sparing agents; BMD z score of
<
= -2 at lumbar spine, proximal femur or distal
forearm
Total participants: n = 31 (9 female); mean (SD) age 26.1 (5.8) years; mean (SD)BMI 21.
1 (2.7) kg/m2; mean (SD) FEV1 50.9 (20.3) % of predicted treatment. Groups similar
with respect to age, initial BMD, bone biochemistry and respiratory disease severity
Treatment group: n = 15 (more females in this group but exact number not reported)
control group: n = 16
3 participants did not complete the study (1 participant in the treatment group received
a double lung transplant and 1 participant in each group died of respiratory failure)
Interventions Treatment group: intravenous pamidronate 30mg every 3months for 6months (2 doses)
plus oral calcium (1 g daily)
Control group: oral calcium (1 g daily)
All participants with pancreatic insufficiency (relevant to all except one in control group)
continued long-term oral vitamin D (900 IU/day)
Outcomes • BMD lumbar spine, proximal femur (total hip) (at 0, 6 months; DXA Hologic
QDR 4500 Waltham MA)
• BMD distal radius, ultra distal radius (at 0, 6 months; SXA)
• Adverse events (bone pain)
• Withdrawals (total, due to adverse events)
• Survival
Notes Received funding from the CF Trust in the UK.
Risk of bias
Bias Authors’ judgement Support for judgement
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Haworth 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but process not
reported.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Not possible to blind as they did not give
placebo infusions, so patients and clini-
cianswould knowwhowas in the treatment
group and who in the control group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals were reported; 1 participant
in each group died of respiratory failure and
1 participant in the treatment group un-
derwent a double lung transplant
Selective reporting (reporting bias) Low risk Outcome measures that were described in
the methods section were reported in the
results section
Other bias High risk Trial duration planned for 1 year, but was
shortened to 6 months because of adverse
events
Haworth 2011
Methods Randomised, double-blinded, placebo-controlled trial; parallel design
Trial duration 24 months.
Multicentre, 4 sites in United Kingdom, 1 site in Ireland.
Participants Inclusion criteria: CF (diagnosis on the basis of a positive sweat test or gene analysis and
a consistent CF phenotype); > 18 years, low BMD defined as lumbar spine, total hip or
femoral neck BMD z score < 1.
Exclusion criteria: prescription of daily oral glucocorticoids for 6 weeks or more in the 12
months preceding the study; breast feeding, pregnancy, desire to become pregnant within
3 years; listed for, or recipient of solid organ transplant; history of gastroscopy proven
oesophageal abnormalities; renal impairment (elevated serumcreatinine and an estimated
creatinine clearance of 30 ml/min or less); hypocalcaemia; previous prescription of
bone active drugs (bisphosphonates, hormone replacement therapy, raloxifene, calcitriol,
calcitonin, teriparatide); biochemical evidence of vitamin D deficiency in the 12 months
prior to the screening visit (25-hydroxyvitamin D level < 10 ng/ml and PTH > 45 pg/
ml); previous poor clinic attendance; previous poor adherence; pre-terminal illness or
other serious concomitant illness
Female participants of reproductive age were advised not to become pregnant for at least
12 months after study completion
Total participants: n = 36 (9 females).
Treatment group: n = 17 (4 females); mean (SD) age 30.2 (12) years
Control group: n = 19 (5 females); mean (SD) age 27.8 (8.0) years
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Haworth 2011 (Continued)
Interventions Treatment group: once weekly oral risedronate 35 mg.
Control group: once weekly identical placebo.
Both groups were both prescribed Calcichew D3 Forte 2 tablets daily which provides
1000 mg calcium + 800 IU vitamin D3/day. Patients were advised to continue their
standard multivitamin supplements
Outcomes • BMD assessed by dual energy x-ray absorptiometry at lumbar spine, total hip and
femoral neck (at baseline, 12 and 24 months)
• Lateral thoracic and lumbar spine x-rays to assess for new vertebral fractures (at
baseline and 24 months)
• Recorded x-ray confirmed fractures (3, 6, 12, 18 and 24 months)
• Adverse events (at 3, 6, 12, 18 and 24 months)
• Biochemical measurements: serum concentration of C-terminal cross-linked
telopeptide of collagen type 1 (CTX) (at baseline and 6-month visits in 24 patients (12
risedronate, 12 placebo)
• Withdrawals
• Survival
Notes Concomitant medications were recorded at study visits (3, 6, 12, 18 and 24 months)
Pregnancy tests were performed in females at study visits (3, 6, 12, 18 and 24 months)
Funded by unrestricted educational grants from Proctor &Gamble (Norwich, USA) and
the Cystic Fibrosis Trust, with support to investigators from the UK National Institute
of Health Research
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were allocated to risedronate or
placebo using a computer programme to
minimise differences between groups in
treatment centre, sex and baseline lumbar
spine BMD
Allocation concealment (selection bias) Low risk Only the study pharmacist had access to
the treatment allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Identical placebo used.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals are described in full and fairly
equally spread across groups
Intervention group: in the first 12
months, 3 out of 17 in the oral risedronate
group withdrew from the study completely
(due to bone pain) and 3 patients discon-
tinued the study medication (one citing
bone pain and the other 2 participants cit-
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ing muscle aches or generalised pain) but
remained in the study for follow up. Be-
tween 12 and 24 months one further par-
ticipant withdrew, citing bone pain. At 24
months, 12 participants in the intervention
group remained in study with 9 still taking
the study drug
Placebo group: immediately after ran-
domisation 1 participant in the placebo
group withdrew consent before taking the
study medication. Therefore, only 18 par-
ticipants were commenced on placebo. By
12 months, 2 participants in the placebo
group withdrew consent and 1 participant
had died. By 24 months, 3 participants
in the placebo group had withdrawn con-
sent and 4 patients had died, hence at 24
months, 12 participants remained in the
control group of the study
Primary outcome data included 12/17 of
risedronate group (although only 9 still on
drug); 12/19 placebo group. In the pub-
lished abstract, it was not clear if the anal-
ysis included the 3 participants
Selective reporting (reporting bias) Low risk Outcome measures that were described in
the methods section were reported in the
results section
Other bias Low risk None identified.
Papaioannou 2008
Methods Randomised, placebo-controlled trial.
Trial duration: 12 months.
Multi-centre, 6 Canadian CF specialty clinics.
Participants Inclusion criteria: participants had CF confirmed by positive sweat test result or DNA
acid analysis and a BMD T score of 1.0, as determined by dual-energy radiograph
absorptiometry
Exclusion criteria: organ transplantation; endoscopy-proven oesophagitis, gastritis, and
ulceration; metabolic bone disorders; severe renal disease; use of systemic corticosteroids
(dose 7.5 mg/day) or other drugs known to influence bone metabolism in the previous
6 months; osteomalacia and other documented contraindications
Total adults randomised: n = 56 (22 female). 9 withdrew, 47 completed study
Treatment group: n = 27 (10 female); mean (SD) age 28.1 (7.7) years. 4 withdrew, 23
completed study
Control group: n = 29 (12 female); mean (SD) age 30.9 (9.7) years. 5 withdrew, 24
completed study
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Interventions Treatment group: oral alendronate (70 mg) once weekly for 12 months
Control group: placebo.
Medication was taken while sitting upright and with water only on an empty stomach
at least 30 min before first food or beverage of the day. In addition,
all participants received 800 IU of vitamin D and 1000 mg of calcium (500 mg supple-
mentation, 500 mg from diet) daily
Outcomes In-clinic assessments at baseline, 6 and 12 months; telephone follow-up conducted by
study staff at months 3 and 9
• Compliance (measured through pill counts at each visit and patient self-report
during telephone contact)
• Physical examination - vital signs (at baseline, 6 and 12 months)
• Biochemical measurements: serum and urine tests (at baseline, 6 and 12 months)
• Pulmonary function tests: including FEV1 and FVC (at baseline, 6 and 12
months)
• Medical Outcomes Study 36-item short form version 2 (SF-36v2) (at baseline, 6
and 12 months)
• Radiographs of the thoracic and lumbar spine, and DXA (at baseline, 6 and 12
months)
• Adverse events and drug reactions (reported spontaneously and at each contact)
Safety analyses included all vertebral fractures, osteoporosis-related fractures, adverse
reactions, and abnormal findings that had been detected through laboratory tests and
physical examinations
Documentation for all adverse events were blinded and adjudicated by the external Data
SafetyMonitoring Committee. All adverse events were reported regardless of attribution
to study medication
Notes Participants who received at least 80% of the study drug were classified as being adherent
to the protocol. 5 participants completed the study protocol but received sub-optimal
dosing (< 80% adherence; treatment group, 3 participants; control group, 2 participants)
. 1 of the participants in the treatment group missed > 50% of doses
Stopping and study withdrawal rules were monitored by an external Data Safety Moni-
toring Committee
During the study, 3 participants in the treatment group used oral corticosteroids com-
pared to none in the control group
Study funding provided by Merck Frosst Canada.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation code,
stratified according to institution was pre-
pared by an independent randomisation
centre and block allocation was employed
to ensure equitable distribution to each
treatment group
33Bisphosphonates for osteoporosis in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Allocation concealment (selection bias) Low risk The randomisation code was prepared by
an independent randomisation centre and
the medication treatment arm was con-
cealed from all participants, central and lo-
cal site coordinators, physicians, staff, and
caregivers
Blinding (performance bias and detection
bias)
All outcomes
Low risk Person(s) responsible for participants care,
participants and outcome assessors were
blinded to treatment group allocation
A medical physicist, who was blinded to
the study treatment arm and study status,
reviewed all DXA scans. Radiographs were
sent to the central methods centre, and
read independently by two radiologistswho
were blinded to the study treatment arm.
Differences between radiologists were re-
solved by consensus
Incomplete outcome data (attrition bias)
All outcomes
Low risk All analyses were performed as intention-
to-treat and included all available data
Withdrawals were described.
Treatment group: 27 randomised, 4 with-
drew (2 non-compliance, 1 due to adverse
event, 1 withdrew consent). 23 completed
study
Control group: 29 randomised, 5withdrew
(2 non-compliance, 2 due to adverse event,
1 lost to follow-up). 24 completed study
Selective reporting (reporting bias) Unclear risk Outcome measures that were described in
the methods section were reported in the
results section. It was reported that there
were no differences in baseline CRP, 25-hy-
droxyvitamin D, PTH or CTX levels be-
tween the risedronate patients who expe-
rienced bone pain and those that did not
(but data not shown)
Other bias Low risk None identified.
ALP: alkaline phosphatase
ALT: alanine aminotransferase
BMD: bone mineral density
BMI: body mass index
CF: cystic fibrosis
DXA: dual-energy x-ray absorptiometry
FEV1: forced expiratory volume in one second
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IU: international units
PTH: parathyroid hormone
SD: standard deviation
SF-36v2: Medical Outcomes Study 36-item short form, version 2
SXA: single energy x-ray absorptiometry
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Conway 2004 This study was a prospective open design, not a randomised controlled trial
Hardin 2005 This study assessed the effect of growth hormone on total-body bone mineral content in pre-pubertal children with
CF. It did not assess the effect of bisphosphonates
CF: cystic fibrosis
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D A T A A N D A N A L Y S E S
Comparison 1. Bisphosphonates versus control (without lung transplantation)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Vertebral fractures 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 12 months 3 107 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 4.21]
1.2 24 months 2 44 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Non-vertebral fractures 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 12 months 2 60 Odds Ratio (M-H, Fixed, 95% CI) 2.11 [0.18, 25.35]
2.2 24 months 2 44 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Total Fractures 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 12 months 3 107 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.13, 3.80]
3.2 24 months 2 44 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Per cent change in BMD, lumbar
spine, DXA (Time-points)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 6 months 4 101 Mean Difference (IV, Fixed, 95% CI) 4.61 [3.90, 5.32]
4.2 12 months 4 136 Mean Difference (IV, Fixed, 95% CI) 6.10 [5.10, 7.10]
4.3 24 months 2 43 Mean Difference (IV, Fixed, 95% CI) 5.49 [4.38, 6.60]
5 Per cent change in BMD, lumbar
spine, DXA (End of study)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 End of study 6 164 Mean Difference (IV, Fixed, 95% CI) 5.67 [4.81, 6.53]
6 Per cent change in BMD,
total hip / femur, DXA
(Time-points)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 6 months 3 96 Mean Difference (IV, Random, 95% CI) 3.35 [1.63, 5.07]
6.2 12 months 4 135 Mean Difference (IV, Random, 95% CI) 4.35 [2.99, 5.70]
6.3 24 months 2 42 Mean Difference (IV, Random, 95% CI) 6.05 [3.74, 8.36]
7 Per cent change in BMD, total
hip/femur, DXA (End of study)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 End of study 5 158 Mean Difference (IV, Random, 95% CI) 4.29 [2.45, 6.13]
8 Per cent change in BMD, distal
radius, SXA (Time-points)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 6 months 2 48 Mean Difference (IV, Random, 95% CI) -0.49 [-2.42, 1.45]
8.2 12 months 1 18 Mean Difference (IV, Random, 95% CI) 0.32 [-0.30, 0.94]
8.3 24 months 1 14 Mean Difference (IV, Random, 95% CI) 1.5 [0.41, 2.59]
9 Per cent change in BMD, distal
radius, SXA (End of study)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 End of study 2 42 Mean Difference (IV, Random, 95% CI) 0.01 [-3.12, 3.14]
10 Per cent change in BMD, ultra
distal radius, SXA
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Quality of Life 1 94 Mean Difference (IV, Fixed, 95% CI) -0.11 [-3.35, 3.12]
11.1 Physical component 1 47 Mean Difference (IV, Fixed, 95% CI) 2.51 [-1.38, 6.40]
11.2 Mental component 1 47 Mean Difference (IV, Fixed, 95% CI) -5.93 [-11.73, -0.13]
12 Bone pain 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Oral bisphosphonates 3 131 Odds Ratio (M-H, Fixed, 95% CI) 43.59 [2.27, 837.56]
36Bisphosphonates for osteoporosis in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
12.2 Intravenous
bisphosphonates
3 60 Odds Ratio (M-H, Fixed, 95% CI) 14.17 [3.64, 55.17]
12.3 All routes of
bisphosphonate administration
6 191 Odds Ratio (M-H, Fixed, 95% CI) 18.52 [5.39, 63.57]
13 Fever 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Oral bisphosphonates 1 48 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 Intravenous
bisphosphonates
3 55 Odds Ratio (M-H, Fixed, 95% CI) 12.64 [2.31, 69.11]
13.3 All routes of
bisphosphonate administration
4 103 Odds Ratio (M-H, Fixed, 95% CI) 12.64 [2.31, 69.11]
14 Withdrawals, due to adverse
events
5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 6 months 2 53 Odds Ratio (M-H, Fixed, 95% CI) 3.95 [0.14, 108.09]
14.2 12 months 4 162 Odds Ratio (M-H, Fixed, 95% CI) 4.07 [1.11, 14.90]
14.3 24 months 2 58 Odds Ratio (M-H, Fixed, 95% CI) 16.34 [1.98, 134.89]
15 Withdrawals, total 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 6 months 2 53 Odds Ratio (M-H, Fixed, 95% CI) 2.83 [0.39, 20.73]
15.2 12 months 3 126 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.38, 2.46]
15.3 24 months 2 58 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.34, 2.69]
16 Survival 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 6 months 2 36 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.05, 16.39]
16.2 12 months 3 140 Odds Ratio (M-H, Fixed, 95% CI) 2.98 [0.30, 29.84]
16.3 24 months 2 58 Odds Ratio (M-H, Fixed, 95% CI) 4.27 [0.43, 42.63]
Comparison 2. Bisphosphonates versus control (with lung transplantation)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Vertebral fractures 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Non-vertebral fractures 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Total Fractures 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Per cent change in BMD, lumbar
spine, DXA
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 24 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Per cent change in BMD, femur,
DXA
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 24 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Bone pain 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Withdrawals, due to adverse
events
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Withdrawals, total 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Survival 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 1
Vertebral fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 1 Vertebral fractures
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 months
Aris 2004 0/20 0/20 Not estimable
Chapman 2009 0/10 0/10 Not estimable
Papaioannou 2008 0/23 2/24 100.0 % 0.19 [ 0.01, 4.21 ]
Subtotal (95% CI) 53 54 100.0 % 0.19 [ 0.01, 4.21 ]
Total events: 0 (Bisphosphonate), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 24 months
Chapman 2009 0/10 0/10 Not estimable
Haworth 2011 0/12 0/12 Not estimable
Subtotal (95% CI) 22 22 Not estimable
Total events: 0 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.2. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 2
Non-vertebral fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 2 Non-vertebral fractures
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 months
Aris 2004 2/20 1/20 100.0 % 2.11 [ 0.18, 25.35 ]
Chapman 2009 0/10 0/10 Not estimable
Subtotal (95% CI) 30 30 100.0 % 2.11 [ 0.18, 25.35 ]
Total events: 2 (Bisphosphonate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 24 months
Chapman 2009 0/10 0/10 Not estimable
Haworth 2011 0/12 0/12 Not estimable
Subtotal (95% CI) 22 22 Not estimable
Total events: 0 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.3. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 3
Total Fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 3 Total Fractures
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 months
Aris 2004 2/20 1/20 27.3 % 2.11 [ 0.18, 25.35 ]
Chapman 2009 0/10 0/10 Not estimable
Papaioannou 2008 0/23 2/24 72.7 % 0.19 [ 0.01, 4.21 ]
Subtotal (95% CI) 53 54 100.0 % 0.72 [ 0.13, 3.80 ]
Total events: 2 (Bisphosphonate), 3 (Control)
Heterogeneity: Chi2 = 1.43, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.39 (P = 0.69)
2 24 months
Chapman 2009 0/10 0/10 Not estimable
Haworth 2011 0/12 0/12 Not estimable
Subtotal (95% CI) 22 22 Not estimable
Total events: 0 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.4. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 4 Per
cent change in BMD, lumbar spine, DXA (Time-points).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 4 Per cent change in BMD, lumbar spine, DXA (Time-points)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 6 months
Aris 2004 24 4.5 (2.45) 24 -1 (2.45) 26.1 % 5.50 [ 4.11, 6.89 ]
Boyle 2005 3 4.7 (0.6) 2 0 (0) Not estimable
Chapman 2009 8 5.35 (0.76) 12 1.19 (1.2) 67.9 % 4.16 [ 3.30, 5.02 ]
Haworth 2001 13 4.1 (3.4) 15 -1.7 (4.4) 6.0 % 5.80 [ 2.91, 8.69 ]
Subtotal (95% CI) 48 53 100.0 % 4.61 [ 3.90, 5.32 ]
Heterogeneity: Chi2 = 3.29, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 12.75 (P < 0.00001)
2 12 months
Aris 2004 20 4.9 (3) 20 -1.8 (4) 20.9 % 6.70 [ 4.51, 8.89 ]
Chapman 2009 9 6.6 (1.5) 10 0.35 (1.55) 53.2 % 6.25 [ 4.88, 7.62 ]
Haworth 2011 14 4.3 (7) 15 -1.2 (6.4) 4.2 % 5.50 [ 0.61, 10.39 ]
Papaioannou 2008 23 5.2 (3.67) 25 -0.08 (3.93) 21.7 % 5.28 [ 3.13, 7.43 ]
Subtotal (95% CI) 66 70 100.0 % 6.10 [ 5.10, 7.10 ]
Heterogeneity: Chi2 = 0.95, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 11.94 (P < 0.00001)
3 24 months
Chapman 2009 10 6.14 (1.86) 9 0.44 (0.1) 92.1 % 5.70 [ 4.55, 6.85 ]
Haworth 2011 12 3.1 (5.5) 12 0.1 (4.3) 7.9 % 3.00 [ -0.95, 6.95 ]
Subtotal (95% CI) 22 21 100.0 % 5.49 [ 4.38, 6.60 ]
Heterogeneity: Chi2 = 1.65, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 9.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.06, df = 2 (P = 0.05), I2 =67%
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Analysis 1.5. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 5 Per
cent change in BMD, lumbar spine, DXA (End of study).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 5 Per cent change in BMD, lumbar spine, DXA (End of study)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of study
Aris 2004 20 4.9 (3) 20 -1.8 (4) 15.3 % 6.70 [ 4.51, 8.89 ]
Boyle 2005 3 4.7 (0.6) 2 0 (0) Not estimable
Chapman 2009 10 6.14 (1.86) 9 0.44 (0.1) 55.2 % 5.70 [ 4.55, 6.85 ]
Haworth 2001 13 4.1 (3.4) 15 -1.7 (4.4) 8.8 % 5.80 [ 2.91, 8.69 ]
Haworth 2011 12 3.1 (5.5) 12 0.1 (4.3) 4.7 % 3.00 [ -0.95, 6.95 ]
Papaioannou 2008 23 5.2 (3.67) 25 -0.08 (3.93) 15.9 % 5.28 [ 3.13, 7.43 ]
Subtotal (95% CI) 81 83 100.0 % 5.67 [ 4.81, 6.53 ]
Heterogeneity: Chi2 = 2.74, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 12.95 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 6 Per
cent change in BMD, total hip / femur, DXA (Time-points).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 6 Per cent change in BMD, total hip / femur, DXA (Time-points)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 6 months
Aris 2004 24 2.2 (2.45) 24 0 (2.45) 36.2 % 2.20 [ 0.81, 3.59 ]
Chapman 2009 8 3.2 (1.6) 12 -1.43 (0.43) 39.2 % 4.63 [ 3.49, 5.77 ]
Haworth 2001 13 1.7 (2.5) 15 -1.3 (3.9) 24.6 % 3.00 [ 0.60, 5.40 ]
Subtotal (95% CI) 45 51 100.0 % 3.35 [ 1.63, 5.07 ]
Heterogeneity: Tau2 = 1.62; Chi2 = 7.32, df = 2 (P = 0.03); I2 =73%
Test for overall effect: Z = 3.83 (P = 0.00013)
2 12 months
Aris 2004 20 2.8 (3.2) 20 -0.7 (4.7) 20.6 % 3.50 [ 1.01, 5.99 ]
Chapman 2009 9 4.12 (1.8) 10 -1.59 (1.4) 38.0 % 5.71 [ 4.25, 7.17 ]
Haworth 2011 13 2.1 (7.3) 15 -1.7 (2.9) 8.9 % 3.80 [ -0.43, 8.03 ]
Papaioannou 2008 23 2.14 (3.32) 25 -1.3 (2.7) 32.5 % 3.44 [ 1.72, 5.16 ]
Subtotal (95% CI) 65 70 100.0 % 4.35 [ 2.99, 5.70 ]
Heterogeneity: Tau2 = 0.71; Chi2 = 4.81, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 6.28 (P < 0.00001)
3 24 months
Chapman 2009 10 4.23 (1.3) 9 -2.5 (1.41) 75.1 % 6.73 [ 5.51, 7.95 ]
Haworth 2011 11 2 (5.8) 12 -2 (3.6) 24.9 % 4.00 [ 0.01, 7.99 ]
Subtotal (95% CI) 21 21 100.0 % 6.05 [ 3.74, 8.36 ]
Heterogeneity: Tau2 = 1.46; Chi2 = 1.65, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 5.13 (P < 0.00001)
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Analysis 1.7. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 7 Per
cent change in BMD, total hip/femur, DXA (End of study).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 7 Per cent change in BMD, total hip/femur, DXA (End of study)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of study
Aris 2004 20 2.8 (3.2) 20 -0.7 (4.7) 19.0 % 3.50 [ 1.01, 5.99 ]
Chapman 2009 10 4.23 (1.3) 9 -2.5 (1.41) 25.9 % 6.73 [ 5.51, 7.95 ]
Haworth 2001 13 1.7 (2.5) 15 -1.3 (3.9) 19.5 % 3.00 [ 0.60, 5.40 ]
Haworth 2011 11 2 (5.8) 12 -2 (3.6) 12.3 % 4.00 [ 0.01, 7.99 ]
Papaioannou 2008 23 2.14 (3.32) 25 -1.3 (2.7) 23.3 % 3.44 [ 1.72, 5.16 ]
Subtotal (95% CI) 77 81 100.0 % 4.29 [ 2.45, 6.13 ]
Heterogeneity: Tau2 = 3.02; Chi2 = 15.14, df = 4 (P = 0.004); I2 =74%
Test for overall effect: Z = 4.57 (P < 0.00001)
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Analysis 1.8. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 8 Per
cent change in BMD, distal radius, SXA (Time-points).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 8 Per cent change in BMD, distal radius, SXA (Time-points)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 6 months
Chapman 2009 8 0.55 (0.93) 12 0.23 (0.89) 60.1 % 0.32 [ -0.50, 1.14 ]
Haworth 2001 13 -1.1 (2.9) 15 0.6 (2.3) 39.9 % -1.70 [ -3.66, 0.26 ]
Subtotal (95% CI) 21 27 100.0 % -0.49 [ -2.42, 1.45 ]
Heterogeneity: Tau2 = 1.45; Chi2 = 3.48, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.49 (P = 0.62)
2 12 months
Chapman 2009 9 0.93 (0.64) 9 0.61 (0.71) 100.0 % 0.32 [ -0.30, 0.94 ]
Subtotal (95% CI) 9 9 100.0 % 0.32 [ -0.30, 0.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
3 24 months
Chapman 2009 7 0.39 (1.17) 7 -1.11 (0.89) 100.0 % 1.50 [ 0.41, 2.59 ]
Subtotal (95% CI) 7 7 100.0 % 1.50 [ 0.41, 2.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.70 (P = 0.0069)
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Analysis 1.9. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 9 Per
cent change in BMD, distal radius, SXA (End of study).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 9 Per cent change in BMD, distal radius, SXA (End of study)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of study
Chapman 2009 7 0.39 (1.17) 7 -1.11 (0.89) 53.4 % 1.50 [ 0.41, 2.59 ]
Haworth 2001 13 -1.1 (2.9) 15 0.6 (2.3) 46.6 % -1.70 [ -3.66, 0.26 ]
Subtotal (95% CI) 20 22 100.0 % 0.01 [ -3.12, 3.14 ]
Heterogeneity: Tau2 = 4.47; Chi2 = 7.83, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.00 (P = 1.0)
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Analysis 1.10. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 10
Per cent change in BMD, ultra distal radius, SXA.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 10 Per cent change in BMD, ultra distal radius, SXA
Study or subgroup Bisphosphonate Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 6 months
Haworth 2001 13 -2.2 (3.5) 15 0.5 (4.3) -2.70 [ -5.59, 0.19 ]
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Analysis 1.11. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 11
Quality of Life.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 11 Quality of Life
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Physical component
Papaioannou 2008 23 -1.18 (4.93) 24 -3.69 (8.33) 68.9 % 2.51 [ -1.38, 6.40 ]
Subtotal (95% CI) 23 24 68.9 % 2.51 [ -1.38, 6.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 Mental component
Papaioannou 2008 23 -2.67 (7.55) 24 3.26 (12.27) 31.1 % -5.93 [ -11.73, -0.13 ]
Subtotal (95% CI) 23 24 31.1 % -5.93 [ -11.73, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.045)
Total (95% CI) 46 48 100.0 % -0.11 [ -3.35, 3.12 ]
Heterogeneity: Chi2 = 5.61, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Chi2 = 5.61, df = 1 (P = 0.02), I2 =82%
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Analysis 1.12. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 12
Bone pain.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 12 Bone pain
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oral bisphosphonates
Aris 2004 0/24 0/24 Not estimable
Haworth 2011 9/17 0/19 100.0 % 43.59 [ 2.27, 837.56 ]
Papaioannou 2008 0/23 0/24 Not estimable
Subtotal (95% CI) 64 67 100.0 % 43.59 [ 2.27, 837.56 ]
Total events: 9 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
2 Intravenous bisphosphonates
Boyle 2005 3/3 0/2 5.5 % 35.00 [ 0.50, 2435.69 ]
Chapman 2009 4/10 2/12 84.5 % 3.33 [ 0.46, 24.05 ]
Haworth 2001 11/15 0/18 10.0 % 94.56 [ 4.65, 1924.08 ]
Subtotal (95% CI) 28 32 100.0 % 14.17 [ 3.64, 55.17 ]
Total events: 18 (Bisphosphonate), 2 (Control)
Heterogeneity: Chi2 = 3.76, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 3.82 (P = 0.00013)
3 All routes of bisphosphonate administration
Aris 2004 0/24 0/24 Not estimable
Boyle 2005 3/3 0/2 4.7 % 35.00 [ 0.50, 2435.69 ]
Chapman 2009 4/10 2/12 72.0 % 3.33 [ 0.46, 24.05 ]
Haworth 2001 11/15 0/18 8.5 % 94.56 [ 4.65, 1924.08 ]
Haworth 2011 9/17 0/19 14.8 % 43.59 [ 2.27, 837.56 ]
Papaioannou 2008 0/23 0/24 Not estimable
Subtotal (95% CI) 92 99 100.0 % 18.52 [ 5.39, 63.57 ]
Total events: 27 (Bisphosphonate), 2 (Control)
Heterogeneity: Chi2 = 4.43, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 4.64 (P < 0.00001)
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Analysis 1.13. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 13
Fever.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 13 Fever
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oral bisphosphonates
Aris 2004 0/24 0/24 Not estimable
Subtotal (95% CI) 24 24 Not estimable
Total events: 0 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Intravenous bisphosphonates
Boyle 2005 1/3 0/2 38.7 % 3.00 [ 0.08, 115.34 ]
Chapman 2009 8/10 1/12 19.7 % 44.00 [ 3.38, 573.41 ]
Haworth 2001 2/13 0/15 41.6 % 6.74 [ 0.29, 154.26 ]
Subtotal (95% CI) 26 29 100.0 % 12.64 [ 2.31, 69.11 ]
Total events: 11 (Bisphosphonate), 1 (Control)
Heterogeneity: Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
3 All routes of bisphosphonate administration
Aris 2004 0/24 0/24 Not estimable
Boyle 2005 1/3 0/2 38.7 % 3.00 [ 0.08, 115.34 ]
Chapman 2009 8/10 1/12 19.7 % 44.00 [ 3.38, 573.41 ]
Haworth 2001 2/13 0/15 41.6 % 6.74 [ 0.29, 154.26 ]
Subtotal (95% CI) 50 53 100.0 % 12.64 [ 2.31, 69.11 ]
Total events: 11 (Bisphosphonate), 1 (Control)
Heterogeneity: Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
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Analysis 1.14. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 14
Withdrawals, due to adverse events.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 14 Withdrawals, due to adverse events
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
Chapman 2009 1/10 0/12 100.0 % 3.95 [ 0.14, 108.09 ]
Haworth 2001 0/15 0/16 Not estimable
Subtotal (95% CI) 25 28 100.0 % 3.95 [ 0.14, 108.09 ]
Total events: 1 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
2 12 months
Aris 2004 0/24 0/24 Not estimable
Chapman 2009 2/10 0/12 14.1 % 7.35 [ 0.31, 173.13 ]
Haworth 2011 6/17 0/19 12.0 % 22.04 [ 1.13, 428.52 ]
Papaioannou 2008 1/27 2/29 73.9 % 0.52 [ 0.04, 6.08 ]
Subtotal (95% CI) 78 84 100.0 % 4.07 [ 1.11, 14.90 ]
Total events: 9 (Bisphosphonate), 2 (Control)
Heterogeneity: Chi2 = 4.07, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 2.12 (P = 0.034)
3 24 months
Chapman 2009 2/10 0/12 56.2 % 7.35 [ 0.31, 173.13 ]
Haworth 2011 7/17 0/19 43.8 % 27.86 [ 1.44, 537.26 ]
Subtotal (95% CI) 27 31 100.0 % 16.34 [ 1.98, 134.89 ]
Total events: 9 (Bisphosphonate), 0 (Control)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0095)
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Analysis 1.15. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 15
Withdrawals, total.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 15 Withdrawals, total
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
Chapman 2009 1/10 0/12 32.1 % 3.95 [ 0.14, 108.09 ]
Haworth 2001 2/15 1/16 67.9 % 2.31 [ 0.19, 28.47 ]
Subtotal (95% CI) 25 28 100.0 % 2.83 [ 0.39, 20.73 ]
Total events: 3 (Bisphosphonate), 1 (Control)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.31)
2 12 months
Aris 2004 4/24 4/24 37.5 % 1.00 [ 0.22, 4.56 ]
Chapman 2009 2/10 2/12 16.4 % 1.25 [ 0.14, 10.94 ]
Papaioannou 2008 4/27 5/29 46.2 % 0.83 [ 0.20, 3.50 ]
Subtotal (95% CI) 61 65 100.0 % 0.96 [ 0.38, 2.46 ]
Total events: 10 (Bisphosphonate), 11 (Control)
Heterogeneity: Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
3 24 months
Chapman 2009 3/10 6/12 52.2 % 0.43 [ 0.07, 2.50 ]
Haworth 2011 8/17 7/19 47.8 % 1.52 [ 0.40, 5.78 ]
Subtotal (95% CI) 27 31 100.0 % 0.95 [ 0.34, 2.69 ]
Total events: 11 (Bisphosphonate), 13 (Control)
Heterogeneity: Chi2 = 1.27, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 0.09 (P = 0.93)
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Analysis 1.16. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 16
Survival.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 16 Survival
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
Boyle 2005 3/3 2/2 Not estimable
Haworth 2001 14/15 15/16 100.0 % 0.93 [ 0.05, 16.39 ]
Subtotal (95% CI) 18 18 100.0 % 0.93 [ 0.05, 16.39 ]
Total events: 17 (Bisphosphonate), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2 12 months
Papaioannou 2008 27/27 29/29 Not estimable
Haworth 2011 17/17 18/19 50.9 % 2.84 [ 0.11, 74.42 ]
Aris 2004 24/24 23/24 49.1 % 3.13 [ 0.12, 80.68 ]
Subtotal (95% CI) 68 72 100.0 % 2.98 [ 0.30, 29.84 ]
Total events: 68 (Bisphosphonate), 70 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
3 24 months
Chapman 2009 10/10 12/12 Not estimable
Haworth 2011 16/17 15/19 100.0 % 4.27 [ 0.43, 42.63 ]
Subtotal (95% CI) 27 31 100.0 % 4.27 [ 0.43, 42.63 ]
Total events: 26 (Bisphosphonate), 27 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
0.01 0.1 1 10 100
Favours pamidronate Favours control
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Analysis 2.1. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 1
Vertebral fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 1 Vertebral fractures
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 3/16 1/18 3.92 [ 0.36, 42.20 ]
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 2.2. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 2 Non-
vertebral fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 2 Non-vertebral fractures
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 3/16 6/18 0.46 [ 0.09, 2.27 ]
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 2.3. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 3 Total
Fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 3 Total Fractures
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 6/16 7/18 0.94 [ 0.24, 3.77 ]
0.01 0.1 1 10 100
Favours treatment Favours control
Analysis 2.4. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 4 Per
cent change in BMD, lumbar spine, DXA.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 4 Per cent change in BMD, lumbar spine, DXA
Study or subgroup Bisphosphonate Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 24 months
Aris 2000 16 8.8 (2.5) 18 2.6 (3.2) 6.20 [ 4.28, 8.12 ]
-10 -5 0 5 10
Favours control Favours pamidronate
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Analysis 2.5. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 5 Per
cent change in BMD, femur, DXA.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 5 Per cent change in BMD, femur, DXA
Study or subgroup Bisphosphonate Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 24 months
Aris 2000 16 8.2 (3.8) 18 0.3 (2.2) 7.90 [ 5.78, 10.02 ]
-10 -5 0 5 10
Favours control Favours pamidronate
Analysis 2.6. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 6 Bone
pain.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 6 Bone pain
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 0/16 0/18 Not estimable
0.5 0.7 1 1.5 2
Favours pamidronate Favours control
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Analysis 2.7. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 7
Withdrawals, due to adverse events.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 7 Withdrawals, due to adverse events
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aris 2000 0/16 0/18 Not estimable
0.01 0.1 1 10 100
Favours treatment Favours control
Analysis 2.8. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 8
Withdrawals, total.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 8 Withdrawals, total
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 0/16 0/18 Not estimable
0.1 0.2 0.5 1 2 5 10
Favours pamidronate Favours control
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Analysis 2.9. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 9
Survival.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 9 Survival
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 16/16 18/18 Not estimable
0.1 0.2 0.5 1 2 5 10
Favours pamidronate Favours control
A P P E N D I C E S
Appendix 1. PubMed search strategy
Search terms
zoledronate AND cystic fibrosis
Appendix 2. PubMed search strategy
Search terms
“Diphosphonates” [Mesh] AND “Cystic Fibrosis” [Mesh]
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WH A T ’ S N E W
Last assessed as up-to-date: 13 March 2014.
Date Event Description
13 April 2015 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 2, 2000
Review first published: Issue 4, 2001
Date Event Description
13 March 2014 New citation required but conclusions have not
changed
Text updated with new references. No new studies
added, hence conclusions remain the same
13 March 2014 New search has been performed A search of the Cystic Fibrosis & Genetic Disorders
Group’s Cystic Fibrosis Trials Register did not identify
any new studies potentially eligible for inclusion in this
review
15 February 2012 New citation required but conclusions have not
changed
One of the new references identified was the full pa-
per publication of a study previously identified as an
e-publication ahead of print and included (Chapman
2009). The other study (two references) has been in-
cluded in this update (Haworth 2011).
A study previously listed as ’Awaiting classification’ has
also now been included (Papaioannou 2008).
15 February 2012 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
identified three new references to two separate studies
26 April 2010 Amended Contact details updated.
18 July 2009 New citation required and conclusions have changed A new review team has updated the review. As part of
this update the sections ’Methods’ and ’Risk of Bias in
included studies’ have been substantively revised and
updated
18 July 2009 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
was run in October 2008. Five references to four new
trials were identified; two trials have been included
(Aris 2004; Chapman 2009) and two trials have been
excluded (Conway 2004; Hardin 2005).
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(Continued)
One newly identified trial has been listed as ’Awaiting
classification’ until the authors have been able to con-
tact the trial investigators (Papaioannou 2008a)
10 November 2004 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
was run in August 2004, but no new references were
identified
12 November 2003 New search has been performed The searches identified no new studies to be included
in the review. Minor style changes have been made
13 November 2002 New search has been performed An additional reference [abstract] to the Haworth
2001 trial has been incorporated into the review
20 August 2001 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Dr Christine Brenckmann and Dr. Alexandra Papaioannou conceived and designed the original review. Until Issue 1, 2005 of The
Cochrane Library, they performed the data collection and interpretation. Christine Brenckmann performed the data management and
analysis, and wrote the review. Christine Brenckmann acted as guarantor of the review until the review team stepped down in 2007.
From Issue 4, 2009 of The Cochrane Library a new review team has taken on this review. The lead author and guarantor of the review
is Dr Louise Conwell. Co-author is Professor Anne Chang.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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External sources
• Australia National Health and Medical Research Council, Australia.
Provision of Practitioner Fellowship for AC
• Queensland Smart State, Australia.
Provision of Clinical Fellowship for AC
I N D E X T E R M S
Medical Subject Headings (MeSH)
Bone Density [∗drug effects]; Bone Density Conservation Agents [adverse effects; ∗therapeutic use]; Cystic Fibrosis [∗complications];
Diphosphonates [adverse effects; ∗therapeutic use]; Fractures, Bone [∗prevention & control]; Lung Transplantation; Osteoporosis
[∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Female; Humans; Male
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